HealthLynked (HLYK) 10-Q 14 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 14, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	HealthLynked Corp
Entity Central Index Key	1,680,139
Trading Symbol	HLYK
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		81,975,927

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current Assets
Cash	$ 38,227	$ 50,006
Accounts receivable, net	141,853	113,349
Prepaid expenses	265,770	81,892
Deferred offering costs	178,421	121,620
Total Current Assets	624,271	366,867
Property, plant and equipment, net of accumulated depreciation of $740,449 and $728,391 as of June 30, 2018 and December 31, 2017, respectively	51,519	63,376
Deposits	9,540	9,540
Total Assets	685,330	439,783
Current Liabilities
Accounts payable and accrued expenses	289,172	253,514
Capital lease, current portion	19,877	18,348
Due to related party, current portion	396,453	363,845
Notes payable to related party, current portion		553,550
Notes payable, net of original issue discount and debt discount of $23,940 and $26,881 as of June 30, 2018 and December 31, 2017, respectively	61,869	70,186
Convertible notes payable, net of original issue discount and debt discount of $689,883 and $266,642 as of June 30, 2018 and December 31, 2017, respectively	350,867	811,858
Derivative financial instruments	1,389,689	398,489
Total Current Liabilities	2,507,927	2,469,790
Long-Term Liabilities
Capital leases, long-term portion	12,232	21,406
Notes payable to related party, long term portion	665,452
Convertible notes payable, long term portion	795,233
Total Liabilities	3,980,844	2,491,196
Shareholders' Deficit
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 77,949,491 and 72,302,937 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	7,795	7,230
Common stock issuable, $0.0001 par value; 18,021 and 122,101 shares as of June 30, 2018 and December 31, 2017, respectively	3,937	8,276
Additional paid-in capital	3,789,341	2,638,311
Accumulated deficit	(7,096,587)	(4,705,230)
Total Shareholders' Deficit	(3,295,514)	(2,051,413)
Total Liabilities and Shareholders' Deficit	$ 685,330	$ 439,783

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Property, plant and equipment, net of accumulated depreciation	$ 740,449	$ 728,391
Original issue discount	23,940	26,881
Convertible notes payable, net of original issue discount and debt discount	$ 689,883	$ 266,642
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	77,949,491	72,302,937
Common stock, shares outstanding	77,949,491	72,302,937
Common stock issuable, par value	$ 0.0001	$ 0.0001
Common stock issuable, shares	18,021	122,101

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue
Patient service revenue, net	$ 566,320	$ 516,798	$ 1,211,959	$ 992,916
Operating Expenses
Salaries and benefits	618,143	495,131	1,178,999	963,005
General and administrative	552,583	498,378	1,127,411	888,404
Depreciation and amortization	6,029	5,859	12,058	11,567
Total Operating Expenses	1,176,755	999,368	2,318,468	1,862,976
(Loss) income from operations	(610,435)	(482,570)	(1,106,509)	(870,060)
Other Income (Expenses)
Gain (loss) on extinguishment of debt	16,864		(308,359)
Change in fair value of debt	(25,452)		(83,398)
Financing cost	(248,443)		(440,505)
Amortization of original issue and debt discounts on notes payable and convertible notes	(244,563)	(58,524)	(399,398)	(130,568)
Change in fair value of derivative financial instrument	52,786		38,165
Interest expense	(51,006)	(20,210)	(91,353)	(37,797)
Total other expenses	(499,814)	(78,734)	(1,284,848)	(168,365)
Net loss before provision for income taxes	(1,110,249)	(561,304)	(2,391,357)	(1,038,425)
Provision for income taxes
Net loss	$ (1,110,249)	$ (561,304)	$ (2,391,357)	$ (1,038,425)
Net loss per share, basic and diluted:
Basic	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)
Fully diluted	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)
Weighted average number of common shares:
Basic	75,871,643	69,411,880	74,397,741	68,028,225
Fully diluted	75,871,643	69,411,880	74,397,741	68,028,225

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Shareholders' Deficit (Unaudited) - 6 months ended Jun. 30, 2018 - USD ($)	Total	Common Stock	Common Stock Issuable	Additional Paid-in Capital	Accumulated Deficit
Balance at Dec. 31, 2017	$ (2,051,413)	$ 7,230	$ 8,276	$ 2,638,311	$ (4,705,230)
Balance, Shares at Dec. 31, 2017		72,302,937
Sale of common stock	499,482	$ 511		498,971
Sale of common stock, Shares		5,105,657
Fair value of warrants allocated to proceeds of common stock	146,021			146,021
Fair value of warrants issued to extend related party notes payable	337,467			337,467
Fair value of warrants issued to extend convertible notes payable	10,199			10,199
Fair value of warrants issued for professional services	115,125			115,125
Consultant fees payable with common shares and warrants	27,356	$ 28	(4,331)	31,659
Consultant fees payable with common shares and warrants, Shares		277,147
Shares and options issued pursuant to employee equity incentive plan	11,606	$ 26	(8)	11,588
Shares and options issued pursuant to employee equity incentive plan, Shares		263,750
Net loss	(2,391,357)				(2,391,357)
Balance at Jun. 30, 2018	$ (3,295,514)	$ 7,795	$ 3,937	$ 3,789,341	$ (7,096,587)
Balance, Shares at Jun. 30, 2018		77,949,491

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash Flows from Operating Activities
Net loss	$ (2,391,357)	$ (1,038,425)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	12,058	11,567
Stock based compensation, including amortization of prepaid fees	97,286	48,650
Amortization of original issue discount and debt discount on convertible notes	399,398	130,568
Financing cost	440,505
Change in fair value of derivative financial instrument	(38,165)
Loss on extinguishment of debt	308,359
Change in fair value of debt	83,398
Changes in operating assets and liabilities:
Accounts receivable	(28,504)	2,273
Prepaid expenses and deposits	(183,878)	15,921
Accounts payable and accrued expenses	45,345	3,322
Due to related party, current portion	32,608	16,488
Net cash used in operating activities	(1,222,947)	(809,636)
Cash Flows from Investing Activities
Acquisition of property and equipment	(201)	(7,046)
Net cash used in investing activities	(201)	(7,046)
Cash Flows from Financing Activities
Proceeds from sale of common stock	645,503	520,000
Proceeds from issuance of convertible notes	805,500	100,000
Repayment of convertible notes	(284,682)
Proceeds from related party loans	101,450	177,470
Repayment of related party loans	(9,000)	(11,192)
Proceeds from notes payable and bank loans	73,500
Repayment of notes payable and bank loans	(113,257)
Payments on capital leases	(7,645)	(9,174)
Net cash provided by financing activities	1,211,369	777,104
Net decrease in cash	(11,779)	(39,578)
Cash, beginning of period	50,006	58,716
Cash, end of period	38,227	19,138
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	9,978	699
Cash paid during the period for income tax
Schedule of non-cash investing and financing activities:
Fair value of warrants issued to extend maturity date of convertible notes payable, recognized as discount against convertible notes payable	10,199	7,506
Fair value of beneficial conversion feature and original issue discount allocated to proceeds of convertible notes payable	1,246,005	66,190
Common stock issuable issued during period	54
Derivative liabilities written off with repayment of convertible notes payable	216,640
Fair value of warrants issued to extend related party notes payable	337,466
Fair of warrants issued for professional service	94,844
Fair value of warrants issued pursuant to Amended Investment Agreement		$ 153,625

Business and Business Presentat

Business and Business Presentation	6 Months Ended
	Jun. 30, 2018
Business and Business Presentation [Abstract]
BUSINESS AND BUSINESS PRESENTATION	NOTE 1 – BUSINESS AND BUSINESS PRESENTATION HealthLynked Corp., a Nevada corporation (the “Company” or “HLYK”) filed its Articles of Incorporation on August 4, 2014. On September 3, 2014 HLYK filed Amended Articles of Incorporation clarifying that the total authorized shares of 250,000,000 shares are broken up between 230,000,000 common shares and 20,000,000 preferred shares. On February 5, 2018, the Company filed the amendment with the Secretary of State of Nevada to increase the amount of authorized shares of common stock to 500,000,000 shares. On September 5, 2014, HLYK entered into a share exchange agreement (the “Share Exchange Agreement”) with Naples Women’s Center LLC (“NWC”), a Florida Limited Liability Company (“LLC”), acquiring 100% of the LLC membership units of NWC through the issuance of 50,000,000 shares of HLYK common stock to the members of NWC (the “Restructuring”). NWC is a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice located in Naples, Florida. HLYK operates an online personal medical information and record archive system, the “HealthLynked Network”, which enables patients and doctors to keep track of medical information via the Internet in a cloud based system. Patients complete a detailed online personal medical history including past surgical history, medications, allergies, and family history. Once this information is entered patients and their treating physicians are able to update the information as needed to provide a comprehensive medical history. These unaudited condensed consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended December 31, 2017 and 2016, respectively, which are included in the Company’s Form 10-K filed with the United States Securities and Exchange Commission on April 2, 2018. The Company assumes that the users of the interim financial information herein have read, or have access to, the audited consolidated financial statements for the preceding period, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context. The results of operations for the three and six months ended June 30, 2018 are not necessarily indicative of results for the entire year ending December 31, 2018. All significant intercompany transactions and balances have been eliminated upon consolidation. In addition, certain amounts in the prior periods’ consolidated financial statements have been reclassified to conform to the current period presentation.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying condensed consolidated financial statements follows: Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets and useful life of fixed assets. Patient Service Revenue Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected charges. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Company does not believe it is required to provide additional goods or services to the patient. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. The Company determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: ● Medicaid: ● Other: Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Cash and Cash Equivalents For financial statement purposes, the Company considers all highly-liquid investments with original maturities of three months or less to be cash and cash equivalents. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 45% of total billings. Trade accounts receivable are recorded at this net amount. As of June 30, 2018 and December 31, 2017, the Company’s gross accounts receivable were $286,728 and $269,501, respectively, and net accounts receivable were $141,853 and $113,349, respectively, based upon net reporting of accounts receivable. Capital Leases Costs associated with capitalized leases are capitalized and depreciated ratably over the term of the related useful life of the asset and/or the capital lease term. The related depreciation was $4,587 and $4,587 for the three months ended June 30, 2018 and 2017, respectively, and $9,174 and $9,174 for the six months ended June 30, 2018 and 2017, respectively. Accumulated depreciation of capitalized leases was $312,912 and $303,738 at June 30, 2018 and December 31, 2017, respectively. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. There was no impairment as of June 30, 2018 and December 31, 2017. Convertible Notes Convertible notes are regarded as compound instruments, consisting of a liability component and an equity component. The component parts of compound instruments are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortized cost basis until extinguished upon conversion or at the instrument’s maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized as additional paid-in capital and included in equity, net of income tax effects, and is not subsequently remeasured. After initial measurement, they are carried at amortized cost using the effective interest method. Convertible notes for which the maturity date has been extended and that qualify for debt extinguishment treatment are recorded at fair value on the extinguishment date and then revalue at the end of each reporting period, with the change recorded to the statement of operations under “Change in Fair Value of Debt.” Derivative Financial Instruments The Company reviews the terms of convertible debt, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received, an immediate charge to income is recognized, in order to initially record the derivative instrument liabilities at their fair value. The discount from the face value of convertible debt instruments resulting from allocating some or all of the proceeds to the derivative instruments is amortized over the life of the instrument through periodic charges to income. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – ● Level 2 ● Level 3 The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs. Stock-Based Compensation The Company accounts for stock based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10") for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, short-term borrowings, accounts payable, accrued liabilities, and derivative financial instruments approximated their fair value. Net Income (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three and six month periods ended June 30, 2018 and 2017, the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of June 30, 2018 and 2017, potentially dilutive securities were comprised of (i) 30,486,790 and 18,566,389 warrants outstanding, respectively, (ii) 2,507,996 and 2,349,996 stock options outstanding, respectively, (iii) 13,238,582 and 7,692,143 shares issuable upon conversion of convertible notes, respectively, and (iv) 440,000 and 622,500 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan. Common stock awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of comprehensive loss in the same manner and charged to the same account as if such settlements had been made in cash. Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 11, Shareholders’ Deficit Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has one operating segment due to business similarities and similar economic characteristics. Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers — Topic 606 In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments — Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In August 2016, the FASB issued ASC Update No. 2016-15, (Topic 230) Classification of Certain Cash Receipts and Cash Payments. This ASC update provides specific guidance on the presentation of certain cash flow items where there is currently diversity in practice, including, but not limited to, debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, and distributions received from equity method investees. The updated guidance is effective for interim and annual periods beginning after December 15, 2017, and should be applied retrospectively unless impracticable. The Company implemented this guidance effective January 1, 2018. The adoption of ASC Update No. 2016-15 did not have a significant impact on the Company’s statement of cash flows. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash restricted cash or restricted cash equivalents in the statement of cash flows. For public business entities, this ASU is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented. The Company will adopt this standard on January 1, 2018 and will not have a material impact on the Company’s financial statements. In January 2017, the FASB issued ASC Update No. 2017-01, (Topic 805) Business Combinations – Clarifying the Definition of a Business. The amendments in this update provide a more robust framework to use in determining when a set of assets and activities constitute a business. This guidance narrows the definition of a business by providing specific requirements that contribute to the creation of outputs that must be present to be considered a business. The guidance further clarifies the appropriate accounting when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets is that of an acquisition (disposition) of assets, not a business. This framework will reduce the number of transactions that an entity must further evaluate to determine whether transactions are business combinations or asset acquisitions. The updated guidance is effective for interim and annual periods beginning after December 15, 2017, and should be applied on a prospective basis. Early adoption is permitted only for transactions that have not been reported in financial statements that have been issued. The Company implemented this guidance effective January 1, 2018. The implementation of this guidance did not have an effect on the Company’s financial position or results of operations. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company’s financial statements. On December 22, 2017 the SEC staff issued Staff Accounting Bulletin 118 (SAB 118), which provides guidance on accounting for the tax effects of the Tax Cuts and Jobs Act (the TCJA). SAB 118 provides a measurement period that should not extend beyond one year from the enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the TCJA for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the TCJA is incomplete but for which they are able to determine a reasonable estimate, it must record a provisional amount in the financial statements. Provisional treatment is proper in light of anticipated additional guidance from various taxing authorities, the SEC, the FASB, and even the Joint Committee on Taxation. If a company cannot determine a provisional amount to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the TCJA. The Company has applied this guidance to its financial statements. In February 2018, the Financial Accounting Standards Board (“FASB”) issued ASC Update No 2018-02 (Topic 220) Income Statement – Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This ASC update allows for a reclassification into retained earnings of the stranded tax effects in accumulated other comprehensive income (“AOCI”) resulting from the enactment of the Tax Cuts and Jobs Act (“TCJA”). The updated guidance is effective for interim and annual periods beginning after December 15, 2018. The Company is evaluating the impact ASU 2018-09 may have on its condensed consolidated financial statements. In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. This standard amends Accounting Standards Codification 740, Income Taxes (ASC 740) to provide guidance on accounting for the tax effects of the Tax Cuts and Jobs Act (the Tax Reform Act) pursuant to Staff Accounting Bulletin No. 118, which allows companies to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard did not materially impact the Company’s financial statements and related disclosures. In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees and supersedes the guidance in Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. Under ASU 2018-07, equity-classified nonemployee share-based payment awards are measured at the grant date fair value on the grant date The probability of satisfying performance conditions must be considered for equity-classified nonemployee share-based payment awards with such conditions. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the new standard on the Company’s Condensed Consolidated Financial Statements. In July 2018, the FASB issued ASU 2018-09 to provide clarification and correction of errors to the Codification. The amendments in this update cover multiple Accounting Standards Updates. Some topics in the update may require transition guidance with effective dates for annual periods beginning after December 15, 2018. The Company is evaluating the impact ASU 2018-09 may have on its condensed consolidated financial statements.

Going Concern Matters and Liqui

Going Concern Matters and Liquidity	6 Months Ended
	Jun. 30, 2018
Going Concern Matters and Liquidity [Abstract]
GOING CONCERN MATTERS AND LIQUIDITY	NOTE 3 – GOING CONCERN MATTERS AND LIQUIDITY As of June 30, 2018, the Company had a working capital deficit of $1,883,656 and accumulated deficit $7,096,587. For the six months ended June 30, 2018, the Company had a net loss of $2,391,357 and net cash used by operating activities of $1,222,947. Net cash used in investing activities was $201. Net cash provided by financing activities was $1,211,369, resulting principally from $805,500 net proceeds from the issuance of convertible notes, $645,503 from the proceeds of the sale of 631,204 shares of common stock and $101,450 proceeds from related party loans. Subsequent to June 30, 2018, the Company completed a $2,000,000 private placement of common stock and warrants with an institutional investor on July 18, 2018. The Company issued 3,900,000 shares of common stock, pre-funded warrants to purchase 4,100,000 shares of common stock, and warrants to purchase 8,000,000 shares of common stock, plus additional warrants to purchase shares of common stock that may become exercisable following the registration of the securities issued in the private placement. The Company’s cash balance and revenues generated are not currently sufficient and cannot be projected to cover its operating expenses for the next twelve months from the date of this report. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include attempting to improve its business profitability and its ability to generate sufficient cash flow from its operations to meet its needs on a timely basis, obtaining additional working capital funds through equity and debt financing arrangements, and restructuring on-going operations to eliminate inefficiencies to raise cash balance in order to meet its anticipated cash requirements for the next twelve months from the date of this report. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures, working capital, and other requirements. Management intends to make every effort to identify and develop sources of funds. The outcome of these matters cannot be predicted at this time. There can be no assurance that any additional financings will be available to the Company on satisfactory terms and conditions, if at all. The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. During July 2016, HLYK entered into an Investment Agreement (the “Investment Agreement”) pursuant to which the investor has agreed to purchase up to $3,000,000 of HLYK common stock over a three-year period starting upon registration of the underlying shares, with such shares put to the investor by the Company pursuant to a specified formula that limits the number of shares able to be put to the investor to the number equal to the average trading volume of the Company’s common shares for the ten consecutive trading days prior to the put notice being issued. During the six months ended June 30, 2018, the Company received $327,818 from the proceeds of the sale of 1,856,480 shares pursuant to the Investment Agreement. The Company intends that the cost of implementing its development and sales efforts related to the HealthLynked Network, as well as maintaining its existing and expanding overhead and administrative costs, will be funded principally by cash received by the Company from the put rights associated with the Investment Agreement and supplemented by other funding mechanisms, including sales of the Company’s common stock, loans from related parties and convertible notes. The Company expects to repay its outstanding convertible notes, which have an aggregate face value of $1,751,750 as of June 30, 2018, from outside funding sources, including but not limited to new convertible notes payable, amounts available upon the exercise of the put rights granted to the Company under the Investment Agreement, sales of equity, loans from related parties and others or through the conversion of the convertible notes into equity. No assurances can be given that the Company will be able to access sufficient outside capital in a timely fashion in order to repay the convertible notes before they mature. If necessary funds are not available, the Company’s business and operations would be materially adversely affected and in such event, the Company would attempt to reduce costs and adjust its business plan.

Deferred Offering Costs and Pre

Deferred Offering Costs and Prepaid Expenses	6 Months Ended
	Jun. 30, 2018
Deferred Offering Costs and Prepaid Expenses [Abstract]
DEFERRED OFFERING COSTS AND PREPAID EXPENSES	NOTE 4 – DEFERRED OFFERING COSTS AND PREPAID EXPENSES Deferred Offering Costs On July 7, 2016, the Company entered into the Investment Agreement with an accredited investor, pursuant to which an accredited investor agreed to invest up to $3,000,000 to purchase the Company’s common stock, par value of $.0001 per share. The purchase price for such shares shall be 80% of the lowest volume weighted average price of the Company’s common stock during the five consecutive trading days prior to the date on which written notice is sent by the Company to the investor stating the number of shares that the Company is selling to the investor, subject to certain discounts and adjustments. Further, for each $50,000 that the investor tenders to the Company for the purchase of shares of common stock, the investor was to be granted warrants for the purchase of an equivalent number of shares of common stock. The warrants were to expire five (5) years from their respective grant dates and have an exercise price equal to 130% of the weighted average purchase price for the respective “$50,000 increment.” On March 22, 2017, the Company and the investor entered into an Amended Investment Agreement (the “Amended Investment Agreement”) whereby the parties agreed to modify the terms of the Investment Agreement by providing that in lieu of granting the investor warrants for each $50,000 that the investor tenders to the Company, the Company granted to the investor warrants to purchase an aggregate of 7,000,000 shares of common stock. The warrants have the following fixed exercise prices: (i) 4,000,000 shares at $0.25 per share; (ii) 2,000,000 shares at $0.50 per share; and (iii) 1,000,000 shares at $1.00 per share. The warrants also contain a “cashless exercise” provision and the shares underlying the warrants will not be registered. The fair value of the warrants was calculated using the Black-Scholes pricing model at $56,635, with the following assumptions: risk-free interest rate of 1.95%, expected life of 5 years, volatility of 40%, and expected dividend yield of zero. On June 7, 2017, the Company also granted warrants to purchase 200,000 shares at $0.25 per share, 100,000 shares at $0.50 per share and 50,000 shares at $1.00 per share to an advisor as a fee in connection with the Amended Investment Agreement. The fair value of the warrants was calculated using the Black-Scholes pricing model at $96,990, with the following assumptions: risk-free interest rate of 1.74%, expected life of 5 years, volatility of 40%, and expected dividend yield of zero. This fair value of the warrants described above was recorded as a deferred offering cost and will be amortized over the period during which the Company can access the financing, which begins the day after a registration statement registering shares underlying the Investment Agreement is declared effective by the United States Securities and Exchange Commission (the “SEC”), and ends 3 years from that date. On May 15, 2017, the SEC declared effective a registration statement registering shares underlying the Investment Agreement. During the three months ended June 30, 2018 and 2017, the Company recognized $12,802 and $6,401, respectively, in general and administrative expense related to the cost of the warrants. During the six months ended June 30, 2018 and 2017, the Company recognized $25,604 and $6,401, respectively, in general and administrative expense related to the cost of the warrants. Prepaid Expenses On June 6, 2018, the Company granted three-year warrants to purchase 600,000 shares at an exercise price of $0.15 per share to two advisors for services to be provided over a six-month period. The fair value of the warrants was calculated using the Black-Scholes pricing model at $94,844, with the following assumptions: risk-free interest rate of 2.65%, expected life of 3 years, volatility of 286.98%, and expected dividend yield of zero. During each of the three and six months ended June 30, 2018, the Company recognized $12,439 in general and administrative expense related to the cost of the warrants.

Property, Plant, and Equipment

Property, Plant, and Equipment	6 Months Ended
	Jun. 30, 2018
Property, Plant, and Equipment [Abstract]
PROPERTY, PLANT, AND EQUIPMENT	NOTE 5 – PROPERTY, PLANT, AND EQUIPMENT Property, plant and equipment at June 30, 2018 and December 31, 2017 are as follows: June 30, December 31, 2018 2017 Capital Lease equipment $ 343,492 $ 343,492 Telephone equipment 12,308 12,308 Furniture, Transport and Office equipment 436,168 435,967 Total Property, plant and equipment 791,968 791,767 Less: accumulated depreciation (740,449 ) (728,391 ) Property, plant and equipment, net $ 51,519 $ 63,376 Depreciation expense during the three months ended June 30, 2018 and 2017 was $6,029 and $5,859, respectively. Depreciation expense during the six months ended June 30, 2018 and 2017 was $12,058 and $11,567, respectively.

Notes Payable and Other Amounts

Notes Payable and Other Amounts Due to Related Party	6 Months Ended
	Jun. 30, 2018
Notes Payable and Other Amounts Due to Related Party [Abstract]
NOTES PAYABLE AND OTHER AMOUNTS DUE TO RELATED PARTY	NOTE 6 – NOTES PAYABLE AND OTHER AMOUNTS DUE TO RELATED PARTY Amounts due to related parties as of June 30, 2018 and December 31, 2017 were comprised of the following: June 30, December 31, 2018 2017 Due to related party: Deferred compensation, Dr. Michael Dent $ 300,600 $ 300,600 Accrued interest payable to Dr. Michael Dent 95,853 63,245 Total due to related party 396,453 363,845 Notes payable to related party: Notes payable to Dr. Michael Dent, current portion --- 553,550 Notes payable to Dr. Michael Dent, long term portion 665,452 --- Total notes payable to related party $ 665,452 $ 553,550 Notes Payable to Dr. Michael Dent Prior to August 2014, NWC was owned and controlled by the Company’s Chief Executive Officer, Dr. Michael Dent (“DMD”). DMD first provided an up to $175,000 unsecured note payable to the Company with a 0% interest rate. During 2013 the limit on the unsecured Note Payable was increased up to $500,000 and during 2014 it was increased to $750,000 with a maturity date of December 31, 2017. During January 2017, the note was again amended to extend the maturity date until December 31, 2018, to accrue interest on outstanding balances after January 1, 2017 at a rate of 10% per annum, and to fix interest accrued on balances between January 1, 2015 and December 31, 2016 at an amount equal to $22,108 (the “$750k DMD Note”). All principal and interest is due at maturity of the $750k DMD Note. Interest accrued on the $750k DMD Note as of June 30, 2018 and December 31, 2017 was $55,665 and $43,963, respectively. The carrying values of notes payable to Dr. Michael Dent as of June 30, 2018 were as follows: Inception Date Maturity Date Borrower Interest Rate Amount January 12, 2017 January 13, 2019 HLYK 10 % $ 39,295 * January 18, 2017 January 19, 2019 HLYK 10 % 22,454 * January 24, 2017 January 15, 2019 HLYK 10 % 56,136 * February 9, 2017 February 10, 2019 HLYK 10 % 33,363 * April 20, 2017 April 21, 2019 HLYK 10 % 10,911 * June 15, 2017 June 16, 2019 HLYK 10 % 34,793 * August 17, 2017 August 18, 2018 HLYK 10 % 20,000 August 24, 2017 August 25, 2018 HLYK 10 % 37,500 September 7, 2017 September 8, 2018 HLYK 10 % 35,000 September 21, 2017 September 22, 2018 HLYK 10 % 26,500 September 29, 2017 September 30, 2018 HLYK 10 % 12,000 December 21, 2017 December 22, 2018 HLYK 10 % 14,000 January 8, 2018 January 9, 2019 HLYK 10 % 75,000 January 11, 2018 January 12, 2019 HLYK 10 % 9,000 January 26, 2018 January 27, 2019 HLYK 10 % 17,450 January 3, 2014 December 31, 2018 NWC 10 % 222,050 $ 665,452 * - Denotes that note payable is carried at fair value On July 18, 2018, in connection with a $2,000,000 private placement by a third party investor, Dr. Dent agreed to extend the maturity date on all of the above notes until December 31, 2019. Interest accrued on the above unsecured promissory notes as of June 30, 2018 and December 31, 2017 was $40,218 and $19,350, respectively. On February 12, 2018, the Company issued a warrant to purchase 6,678,462 shares of common stock to DMD as an inducement to (i) extend the maturity dates of up to $439,450 loaned by Dr. Dent to the Company in 2017 and 2018 in the form of unsecured promissory notes, including $75,000 loaned from Dr. Dent to the Company in January 2018 to allow the Company to retire an existing convertible promissory note payable to Power-up Lending Group Ltd. before such convertible promissory note became eligible for conversion, and (ii) provide continued loans to the Company. The warrant is immediately exercisable at an exercise price of $0.065 per share, subject to adjustment, and expires five years after the date of issuance. The fair value of the warrants was calculated using the Black-Scholes pricing model at $337,466, with the following assumptions: risk-free interest rate of 2.56%, expected life of 5 years, volatility of 268.90%, and expected dividend yield of zero. On March 28, 2012, DMD agreed to extend the maturity dates of promissory notes with an aggregate face value of $177,500, which were originally scheduled to mature before June 30, 2018, by one year from the original maturity date. Because the fair value of the warrants was greater than 10% of the present value of the remaining cash flows under the modified promissory notes, the transaction was treated as a debt extinguishment and reissuance of new debt instruments pursuant to the guidance of ASC 470-50 “Debt – Modifications and Extinguishments” (“ASC 470-50"). A loss on debt extinguishment was recorded in the amount of $348,938, equal to the fair value of the warrants of $337,466, plus the excess of $11,472 of the fair value of the reissued debt instruments over the carrying value of the existing debt instruments. The change in fair value of the reissued debt instruments subsequent to the reissuance date was $4,532 in the three months ended June 30, 2018 and $7,981 in the six months ended June 30, 2018, which is included in “Change in fair value of debt.” MedOffice Direct During 2017, the Company entered into an agreement with MedOffice Direct (“MOD”), a company majority-owned by the Company’s CEO and largest shareholder, Dr. Michael Dent, pursuant to which the Company will pay rent to MOD in the amount of $2,040 per month for office space in MOD’s facility used by the Company and its employees for the period from January 1, 2017 through July 31, 2018. During the three months ended June 30, 2018 and 2017, the Company recognized rent expense to MOD in the amount of $6,120 and $6,120, respectively. During the six months ended June 30, 2018 and 2017, the Company recognized rent expense to MOD in the amount of $12,240 and $12,240, respectively. The Company had prepaid an additional $18,217 toward future rent as of June 30, 2018. During 2017, the Company entered into a separate Marketing Agreement with MOD pursuant to which MOD agreed to market the HealthLynked Network to its physician practice clients, in exchange for a semi-annual fee of $25,000. This agreement was terminated effective April 1, 2018. During the three months ended June 30, 2018 and 2017, the Company recognized general and administrative expense in the amount of $-0- and $25,000, respectively, pursuant to this agreement. During the six months ended June 30, 2018 and 2017, the Company recognized general and administrative expense in the amount of $12,500 and $25,000, respectively, pursuant to this agreement. On July 1, 2018 HLYK and MOD signed a marketing and service agreement where HLYK will include MOD offering as part of its product offering to Physicians and HLYK will receive 8% of revenue for new sales related to MOD products sold by the HLYK sales team. The revenue percentage will be split between HLYK and the HLYK sales representative.

Capital Lease

Capital Lease	6 Months Ended
	Jun. 30, 2018
Capital Lease [Abstract]
CAPITAL LEASE	NOTE 7 – CAPITAL LEASE Capital lease obligations as of June 30, 2018 and December 31, 2017 are comprised of the following: June 30, December 31, 2018 2017 Note payable, New Everbank Lease $ 32,109 $ 39,754 Less: note payable, New Everbank Lease (Capital leases), current portion (19,877 ) (18,348 ) Notes payable, bank loans and capital leases, long-term portion $ 12,232 $ 21,406 In March 2015, the Company entered into a capital equipment finance lease for Ultra Sound equipment with Everbank. There was no interest on this lease. The monthly payment is $1,529 for 60 months ending in March 2020. As of June 30, 2018, the Company owed Everbank $32,109 pursuant to this capital lease. During the three months ended June 30, 2018 and 2017, the Company made payments on this capital lease of $4,587 and $4,587, respectively. During the six months ended June 30, 2018 and 2017, the Company made payments on this capital lease of $7,645 and $9,174, respectively. Future minimum payments to which the Company is obligated pursuant to the capital leases as of June, 2018 are as follows: 2018 (July to December) $ 10,703 2019 18,348 2020 3,058 2021 --- 2022 --- Total $ 32,109

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2018
Notes Payable/Convertible Notes Payable [Abstract]
NOTES PAYABLE	NOTE 8 – NOTES PAYABLE On December 20, 2017, the Company entered into a Merchant Cash Advance Factoring Agreement (“MCA”) with Power Up Lending Group, Ltd. (the “PULG”) pursuant to which the Company received an advance of $75,000 before closing fees (the “December MCA”). The Company is required to repay the advance, which acts like an ordinary note payable, at the rate of $4,048 per week until the balance of $102,000 has been repaid in June 2018. At inception, the Company recognized a note payable in the amount of $102,000 and a discount against the note payable of $28,500. The discount was being amortized over the life of the instrument. During the six months ended June 30, 2018, the Company made installment payments of $89,048. The December MCA was repaid on June 1, 2018. During the six months ended June 30, 2018, the Company recognized amortization of the discount in the amount of $26,881, including $2,267 recognized to amortize the remaining discount at retirement. On June 1, 2018, the Company entered into a new MCA with PULG pursuant to which the Company received an advance of $75,000 before closing fees (the “December MCA”). The Company is required to repay the advance at the rate of $4,048 per week until the balance of $102,000 has been repaid in November 2018. At inception, the Company recognized a note payable in the amount of $102,000 and a discount against the note payable of $28,500. The discount is being amortized over the life of the instrument. During the three and six months ended June 30, 2018, the Company recognized amortization of the discount in the amount of $4,560. As of June 30, 2018, the net carrying value of the instrument was $61,869.

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2018
Notes Payable/Convertible Notes Payable [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 9 – CONVERTIBLE NOTES PAYABLE Convertible notes payable as of June 30, 2018 and December 31, 2017 are comprised of the following: June 30, December 31, 2018 2017 $550k Note - July 2016 $ 612,409 * $ 550,000 $50k Note - July 2016 59,771 * 50,000 $111k Note - May 2017 123,053 * 111,000 $53k Note - July 2017 --- 53,000 $35k Note - September 2017 --- 35,000 $55k Note - September 2017 --- 55,000 $53k Note II - October 2017 --- 53,000 $171.5k Note - October 2017 171,500 171,500 $57.8k Note - January 2018 57,750 --- $112.8k Note - February 2018 112,750 --- $83k Note - February 2018 83,000 --- $105k Note - March 2018 105,000 --- $63k Note - April 2018 63,000 --- $57.8k Note - April 2018 57,750 --- $90k Note - April 2018 90,000 --- $53k Note II - April 2018 53,000 --- $68.3k Note - May 2018 68,250 --- $37k Note May 2018 37,000 --- $63k Note II - May 2018 63,000 --- $78.8k Note - May 2018 78,750 --- 1,835,983 1,078,500 Less: unamortized discount (689,883 ) (266,642 ) Convertible notes payable, net of original issue discount and debt discount 1,146,100 811,858 Less: convertible notes payable, long term portion (795,233 ) --- Convertible notes payable, current portion $ 350,867 $ 811,858 * - Denotes that convertible note payable is carried at fair value Convertible Notes Payable ($550,000) – July 2016 On July 7, 2016, the Company entered into a 6% fixed convertible secured promissory note with an investor with a face value of $550,000 (the “$550k Note”). The $550k Note is convertible into shares of the Company’s common stock at the discretion of the note holder at a fixed price of $0.08 per share, and is secured by all of the Company’s assets. The Company received $500,000 net proceeds from the note after a $50,000 original issue discount. The $550k Note was originally scheduled to mature on April 11, 2017, but the maturity date was extended to July 7, 2018 during August 2017 and to December 31, 2019 during July 2018. The discount from the original issue discount, warrants and embedded conversion feature (“ECF”) associated with the $550k Note was amortized over the original life of the note. There was no amortization of such discounts in the three or six months ended June 30, 2018 or 2017. As of June 30, 2018, the unamortized discount was $-0- and the $550k Note was convertible into 6,875,000 of the Company’s common shares. The $550k Note is carried at fair value due to an extinguishment and reissuance recorded in 2017 and is revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” The fair value of this instrument as of June 30, 2018 was $612,408. During the three months ended June 30, 2018 and 2017, a change in fair value of debt related to this instrument was recorded in the amount of $16,110 and $-0-, respectively. During the six months ended June 30, 2018 and 2017, a change in fair value of debt related to this instrument was recorded in the amount of $62,408 and $-0-, respectively. During the six months ended June 30, 2018 and 2017, the Company made no repayments on this instrument. During the three months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $8,227 and $8,227, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $16,364 and $16,364, respectively. Convertible Notes Payable ($50,000) – July 2016 On July 7, 2016, the Company entered into a 10% fixed convertible commitment fee promissory note with an investor with a face value of $50,000 (the “$50k Note”). The $50k Note was originally scheduled to mature on April 11, 2017, but the maturity date was extended to July 11, 2018 during August 2017 and to December 31, 2019 during July 2018. The $50k note was issued as a commitment fee payable to the Investment Agreement investor in exchange for the investor’s commitment to enter into the Investment Agreement, subject to registration of the shares underlying the Investment Agreement. The $50k Note is convertible into shares of the Company’s common stock at the discretion of the note holder at a fixed price of $0.10 per share. As of June 30, 2018, the $50k Note was convertible into 500,000 of the Company’s common shares. The $50k Note is carried at fair value due to an extinguishment and reissuance recorded in 2017 and is revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” The fair value of this instrument as of June 30, 2018 was $59,771. During the three months ended June 30, 2018 and 2017, a change in fair value of debt related to this instrument was recorded in the amount of $1,572 and $-0-, respectively. During the six months ended June 30, 2018 and 2017, a change in fair value of debt related to this instrument was recorded in the amount of $9,771 and $-0, respectively. During the six months ended June 30, 2018 and 2017, the Company made no repayments on this instrument. During the three months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $1,247 and $1,247, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $2,479 and $2,479, respectively. Convertible Notes Payable ($111,000) – May 2017 On May 22, 2017, the Company entered into a 10% fixed convertible secured promissory note with an investor with a face value of $111,000 (the “$111k Note”). The $111k Note is convertible into shares of the Company’s common stock at the discretion of the note holder at a fixed price of $0.35 per share, and is secured by all of the Company’s assets. The Company received $100,000 net proceeds from the note after an $11,000 original issue discount. At inception, the investors were also granted a five-year warrant to purchase 133,333 shares of the Company’s common stock at an exercise price of $0.75 per share. On March 28, 2018, in exchange for a five-year warrant to purchase 125,000 shares of HLYK common stock at an exercise price of $0.05 per share, the holder of the $111k Note agreed to extend the maturity date from the original date of January 22, 2018 until July 11, 2018. The fair value of the warrants using Black/Scholes was $10,199 with the following assumptions: risk-free interest rate of 2.59%, expected life of 5 years, volatility of 578.45%, and expected dividend yield of zero. The issuance of the warrants in exchange for the maturity extension was treated as an extinguishment and reissuance of existing debt pursuant to the guidance of ASC 470-50. Accordingly, the $111k Note is carried at fair value and is revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” The fair value of this instrument as of June 30, 2018 was $123,503. During the three months ended June 30, 2018 and 2017, a change in fair value of debt related to this instrument was recorded in the amount of $3,238 and $-0-, respectively. During the six months ended June 30, 2018 and 2017, a change in fair value of debt related to this instrument was recorded in the amount of $3,238 and $-0, respectively. In July 2018, the maturity was further extended until December 31, 2019. Amortization expense related to discounts on this instrument in the three months ended June 30, 2018 and 2017 was $-0- and $12,287, respectively. Amortization expense related to discounts in the six months ended June 30, 2018 and 2017 was $6,931and $12,287, respectively. As of June 30, 2018, the unamortized discount was $-0-. As of June 30, 2018, this instrument was convertible into 317,143 of the Company’s common shares. During the six months ended June 30, 2018 and 2017, the Company made no repayments on this instrument. During the three months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $4,078 and $1,767, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $8,246 and $1,767, respectively. Convertible Notes Payable ($53,000) – July 2017 On July 10, 2017, the Company entered into a securities purchase agreement for the sale of a $53,000 convertible note (the “$53k Note”) to PULG. The $53k Note included a $3,000 original issue discount, for net proceeds of $50,000. The $53k Note has an interest rate of 10% and a default interest rate of 22%. The $53k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the $53k Note, 150% of the outstanding principal and any interest due amount shall be immediately due. The discount resulting from the original issue discount and embedded conversion feature was being amortized over the life of the $53k Note, which was schedule to mature on April 15, 2018. Amortization expense related to the discount in the three months ended June 30, 2018 and 2017 was $1,520 and $-0-, respectively and amortization expense in the six months ended June 30, 2018 and 2017 was $1,520 and $-0-. On January 8, 2018, the Company prepaid the balance on the $53k Note, including accrued interest, for a one-time cash payment of $74,922. The Company recognized a gain on debt extinguishment in the six months ended June 30, 2018 in connection with the repayment, as follows: Cash repayment $ 74,922 Less face value of convertible note payable retired (53,000 ) Less carrying value of derivative financial instruments arising from ECF (53,893 ) Less accrued interest (2,644 ) Plus carrying value of discount at extinguishment 18,427 Gain on extinguishment of debt $ (16,188 ) Convertible Notes Payable ($35,000) – September 2017 On September 7, 2017, the Company entered into a securities purchase agreement for the sale of a $35,000 convertible note (the “$35k Note”) to PULG. The $35k Note included a $3,000 original issue discount, for net proceeds of $32,000. The $35k Note has an interest rate of 10% and a default interest rate of 20%. The $35k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the $35k Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the $35k Note, 150% of the outstanding principal and any interest due amount shall be immediately due. The discount resulting from the original issue discount and embedded conversion feature was being amortized over the life of the $35k Note, which was schedule to mature on June 15, 2018. Amortization expense related to the discount in the three months ended June 30, 2018 and 2017 was $614 and $-0-, respectively, and in the six months ended June 30, 2018 and 2017 was $614 and $-0-, respectively. On March 5, 2018, the Company prepaid the balance on the $35k Note, including accrued interest, for a one-time cash payment of $49,502. The Company recognized a gain on debt extinguishment in the six months ended June 30, 2018 in connection with the repayment, as follows: Cash repayment $ 49,502 Less face value of convertible note payable retired (35,000 ) Less carrying value of derivative financial instruments arising from ECF (37,269 ) Less accrued interest (1,716 ) Plus carrying value of discount at extinguishment 12,705 Gain on extinguishment of debt $ (11,778 ) Convertible Notes Payable ($55,000) – September 2017 On September 11, 2017, the Company entered into a securities purchase agreement for the sale of a $55,000 convertible note (the “$55k Note”) to Crown Bridge Partners LLC. The $55k Note included a $7,500 original issue discount, for net proceeds of $47,500. The 55k Note has an interest rate of 10% and a default interest rate of 12%. The $55k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 60% multiplied by the lowest one (1) trading price for the Common Stock during the twenty (20) trading day period ending on the last complete trading day prior to the date of conversion. If, at any time while the $55k Note is outstanding, the conversion price pursuant to this formula is equal to or lower than $0.10, then an additional ten percent (10%) discount shall be factored into the conversion price until the $55k Note is no longer outstanding. In the event that shares of the Company’s Common Stock are not deliverable via DWAC following the conversion of any amount hereunder, an additional ten percent (10%) discount shall be factored into the Variable Conversion Price until the $55k Note is no longer outstanding. The discount resulting from the original issue discount and embedded conversion feature was being amortized over the life of the $55k Note, which was schedule to mature on September 11, 2018. Amortization expense related to the discount in the three months ended June 30, 2018 and 2017 was $1,085 and $-0-, respectively, and in the six months ended June 30, 2018 and 2017 was $1,085 and $-0-, respectively. On March 13, 2018, the Company prepaid the balance on the $55k Note, including accrued interest, for a one-time cash payment of $85,258. The Company recognized a gain on debt extinguishment in the six months ended June 30, 2018 in connection with the repayment, as follows: Cash repayment $ 85,258 Less face value of convertible note payable retired (55,000 ) Less carrying value of derivative financial instruments arising from ECF (69,687 ) Less accrued interest (2,759 ) Plus carrying value of discount at extinguishment 27,425 Gain on extinguishment of debt $ (14,763 ) Convertible Notes Payable ($53,000) – October 2017 On October 23, 2017, the Company entered into a securities purchase agreement for the sale of a $53,000 convertible note (the “$53k Note II”) to PULG. The $53k Note II included a $3,000 original issue discount, for net proceeds of $50,000. The $53k Note II has an interest rate of 10% and a default interest rate of 20%. The $53k Note II may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due. The discount resulting from the original issue discount and embedded conversion feature was being amortized over the life of the $53k Note II, which was schedule to mature on July 30, 2018. Amortization expense related to the discount in the three months ended June 30, 2018 and 2017 was $3,407 and $-0-, respectively, and in the six months ended June 30, 2018 and 2017 was $20,443 and $-0-, respectively. On April 18, 2018, the Company prepaid the balance on the $53k Note II, including accrued interest, for a one-time cash payment of $75,000. The Company recognized a gain on debt extinguishment in the six months ended June 30, 2018 in connection with the repayment, as follows: Cash repayment $ 75,000 Less face value of convertible note payable retired (53,000 ) Less carrying value of derivative financial instruments arising from ECF (55,790 ) Less accrued interest (2,571 ) Plus carrying value of discount at extinguishment 19,496 Gain on extinguishment of debt $ (16,865 ) Convertible Notes Payable ($171,500) – October 2017 On October 27, 2017, the Company entered into a securities purchase agreement for the sale of a $171,500 convertible note (the “$171.5k Note”) to an individual lender. The $171.5k Note included a $21,500 original issue discount, for net proceeds of $150,000. The $171.5k Note has an interest rate of 10% and a default interest rate of 22% and matures on October 26, 2018. The $171.5k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 35% discount to the lowest closing bid price during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the $171.5k Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the $171.5k Note, 150% of the outstanding principal and any interest due amount shall be immediately due. Amortization expense related to discounts on this instrument in the three months ended June 30, 2018 and 2017 was $42,875 and $-0-, respectively. Amortization expense related to discounts in the six months ended June 30, 2018 and 2017 was $85,279 and $-0-, respectively. As of June 30, 2018, the unamortized discount was $55,596. During the six months ended June 30, 2018 and 2017, the Company made no repayments on this instrument. During the three months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $4,276 and $-0-, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $8,504 and $-0-, respectively. Convertible Notes Payable ($57,750) – January 2018 On January 2, 2018, the Company entered into a securities purchase agreement for the sale of a $57,750 convertible note (the “$58k Note”). The transaction closed on January 3, 2018. The $58k Note included a $5,250 original issue discount and $2,500 fee for net proceeds of $50,000. The $58k Note has an interest rate of 10% and a default interest rate of 18% and matures on January 2, 2019. The $58k Note was convertible into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. On June 26, 2018, the holder agreed, without consideration, to reduce the discount to 28% of the volume weighted average price of the Company’s common stock for the 10 days prior to the conversion date. Because this the change in terms resulted in a decrease to the value of the ECF, no amounts were recorded to reflect the change in terms. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the Note, 200% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due. The fair value of the ECF of the $58k Note was calculated using the Black-Scholes pricing model at $82,652, with the following assumptions: risk-free interest rate of 1.83%, expected life of 1 year, volatility of 264.29%, and expected dividend yield of zero. Because the fair value of the ECF exceeded the net proceeds from the $58k Note, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $82,652 over the net proceeds from the note of $50,000, for a net charge of $32,652. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 82,652 Original issue discount and fees 7,750 Financing cost (32,652 ) Convertible note --- Notes payable and bank loans, long-term portion $ 57,750 Amortization expense related to discounts on this instrument in the three months ended June 30, 2018 and 2017 was $14,398 and $-0-, respectively. Amortization expense related to discounts in the six months ended June 30, 2018 and 2017 was $28,321and $-0-, respectively. As of June 30, 2018, the unamortized discount was $29,429. During the six months ended June 30, 2018 and 2017, the Company made no repayments on this instrument. During the three months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $1,440 and $-0-, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $2,832 and $-0-, respectively. Convertible Notes Payable ($112,750) – February 2018 On February 2, 2018, the Company entered into a securities purchase agreement for the sale of a $112,750 convertible note (the “$113k Note”). The transaction closed on February 8, 2018. The $113k Note included $12,750 fees for net proceeds of $100,000. The $113k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 2, 2019. The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the Note, 200% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due. The fair value of the ECF of the $113k Note was calculated using the Black-Scholes pricing model at $161,527, with the following assumptions: risk-free interest rate of 1.88%, expected life of 1 year, volatility of 264.93%, and expected dividend yield of zero. Because the fair value of the ECF exceeded the net proceeds from the $113k Note, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $161,527 over the net proceeds from the note of $100,000, for a net charge of $61,527. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 161,527 Original issue discount and fees 12,750 Financing cost (61,527 ) Convertible note --- Notes payable and bank loans, long-term portion $ 112,750 The discounts resulting from the original issue discount, warrants and embedded conversion feature are being amortized over the life of the $113k Note. Amortization expense related to discounts on this instrument in the three months ended June 30, 2018 and 2017 was $28,110 and $-0-, respectively. Amortization expense related to discounts in the six months ended June 30, 2018 and 2017 was $45,718 and $-0-, respectively. As of June 30, 2018, the unamortized discount was $67,032. During the six months ended June 30, 2018 and 2017, the Company made no repayments on this instrument. During the three months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $2,811 and $-0-, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $4,572 and $-0-, respectively. Convertible Notes Payable ($83,000) – February 2018 On February 13, 2018, the Company entered into a securities purchase agreement for the sale of a $83,000 convertible note (the “$83k Note”). The transaction closed on February 21, 2018. The $83k Note included $8,000 fees for net proceeds of $75,000. The $83k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 13, 2019. The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 200% of the outstanding principal and any interest due amount shall be immediately due. The fair value of the ECF of the $83k Note was calculated using the Black-Scholes pricing model at $119,512, with the following assumptions: risk-free interest rate of 1.95%, expected life of 1 year, volatility of 268.44%, and expected dividend yield of zero. Because the fair value of the ECF exceeded the net proceeds from the $83k Note, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $119,512 over the net proceeds from the note of $75,000, for a net charge of $44,512. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 119,512 Original issue discount and fees 8,000 Financing cost (44,512 ) Convertible note --- Notes payable and bank loans, long-term portion $ 83,000 The discounts resulting from the original issue discount, warrants and embedded conversion feature are being amortized over the life of the $83k Note. Amortization expense related to discounts on this instrument in the three months ended June 30, 2018 and 2017 was $20,693 and $-0-, respectively. Amortization expense related to discounts in the six months ended June 30, 2018 and 2017 was $31,153 and $-0-, respectively. As of June 30, 2018, the unamortized discount was $51,847. During the six months ended June 30, 2018 and 2017, the Company made no repayments on this instrument. During the three months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $2,069 and $-0-, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $3,115 and $-0-, respectively. Convertible Notes Payable ($105,000) – March 2018 On March 5, 2018, the Company entered into a securities purchase agreement for the sale of a $105,000 convertible note (the “$105k Note”). The transaction closed on March 12, 2018. The $105k Note included $5,000 fees for net proceeds of $100,000. The $105k Note has an interest rate of 10% and a default interest rate of 24% and matures on March 5, 2019. The $113k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 9.9% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 110-150% of the outstanding principal and any interest due amount shall be immediately due, depending on the nature of the breach. The fair value of the ECF of the $105k Note was calculated using the Black-Scholes pricing model at $153,371, with the following assumptions: risk-free interest rate of 2.06%, expected life of 1 year, volatility of 278.96%, and expected dividend yield of zero. Because the fair value of the ECF exceeded the net proceeds from the $105k Note, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $153,371 over the net proceeds from the note of $100,000, for a net charge of $53,371. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 153,371 Original issue discount and fees 5,000 Financing cost (53,371 ) Convertible note --- Notes payable and bank loans, long-term portion $ 105,000 The discounts resulting from the original issue discount, warrants and embedded conversion feature are being amortized over the life of the $105k Note. Amortization expense related to discounts on this instrument in the three months ended June 30, 2018 and 2017 was $26,178 and $-0-, respectively. Amortization expense related to discounts in the six months ended June 30, 2018 and 2017 was $33,658 and $-0-, respectively. As of June 30, 2018, the unamortized discount was $71,342. During the six months ended June 30, 2018 and 2017, the Company made no repayments on this instrument. During the three months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $2,618 and $-0-, respectively. During the six months ended June 30, 2018 and 2017, the Company recorded interest expense on this instrument totaling $3,366 and $-0-, respectively. Convertible Notes Payable ($63,000) – April 2018 On April 2, 2018, the Company entered into a securities purchase agreement for the sale of a $63,000 convertible note (the “$63k Note”). The transaction closed on April 3, 2018. The $63k Note included $3,000 fees for net proceeds of $60,000. The $63k Note has an interest rate of 10% and a default interest rate of 22% and matures on January 15, 2019. The $63k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the lowest bid or trading price of the Company’s common stock during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due. The fair value of the ECF of the $63k Note was calculated using the Black-Scholes pricing model at $83,806, with the following assumptions: risk-free interest rate of 2.08%, expected life of 0.79 years, volatility of 260.76%, and expected dividend yield of zero. Because the fair value of the ECF exceeded the net proceeds, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $83,806 over the net proceeds from the note of $60,000, for a net charge of $23,806. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 83,806 Original issue discount and fees 3,000 Financing cost (23,806 ) Convertible note --- Notes payable and bank loans, long-term portion $ 63,000 The discounts resulting from the original issue discount, warrants and embedded conversion feature are being amortized over the life of the note. Amortization expense related to discounts on this instrument in the three and six months ended June 30, 2018 was $19,469. As of June 30, 2018, the unamortized discount was $43,531. During the six months ended June 30, 2018 and 2017, the Company made no repayments on this instrument. During the thre

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2018
Derivative Financial Instruments [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS	NOTE 10 – DERIVATIVE FINANCIAL INSTRUMENTS Derivative financial instruments are comprised of the fair value of conversion features embedded in convertible promissory notes for which the conversion rate is not fixed, but instead is adjusted based on a discount to the market price of the Company’s common stock. The fair market value of the derivative liabilities was calculated at inception of each convertible promissory notes for which the conversion rate is not fixed and allocated to the respective convertible notes, with any excess recorded as a charge to “Financing cost.” The derivative financial instruments are then revalued at the end of each period, with the change in value recorded to “Change in fair value of on derivative financial instruments.” Derivative financial instruments and changes thereto recorded in the six months ended June 30, 2018 include the following: Change in Fair Value Inception of Fair Value Write off Fair Value as of Derivative of Derivative Derivative as of December 31, Financial Financial Financial June 30, 2017 Instruments Instruments Instruments 2018 $53k Note - July 2017 $ 48,876 $ --- $ 5,017 $ (53,893 ) $ --- $35k Note - September 2017 36,161 --- 1,108 (37,269 ) --- $55k Note - September 2017 64,656 --- 5,032 (69,688 ) --- $53k Note #2 - October 2017 58,216 --- (2,426 ) (55,790 ) --- $171.5k Note - October 2017 190,580 --- (7,953 ) --- 182,627 $57.8k Note - January 2018 --- 82,652 (21,229 ) --- 61,423 $112.8k Note - February 2018 --- 161,527 (8,207 ) --- 153,320 $83k Note - February 2018 --- 119,512 (5,433 ) --- 114,079 $105k Note - March 2018 --- 153,371 (6,482 ) --- 146,889 $63k Note - April 2018 --- 83,806 234 --- 84,040 $57.8k Note - April 2018 --- 83,397 (51 ) --- 83,346 $90k Note - April 2018 --- 130,136 (78 ) --- 130,058 $53k Note II - April 2018 --- 71,679 172 --- 71,851 $68.3k Note - May 2018 --- 99,422 189 --- 99,611 $37k Note May 2018 --- 54,086 11 --- 54,097 $63k Note II - May 2018 --- 90,390 1,721 --- 92,111 $78.8k Note - May 2018 --- 116,027 210 --- 116,237 $ 398,489 $ 1,246,005 $ (38,165 ) $ (216,640 ) $ 1,389,689 During the six months ended June 30, 2018, the $53k Note, the $35k Note, the $55k Note, and the $53k Note II were each repaid in full. Accordingly, the derivative financial instruments associated with the ECFs of these convertible notes were written off in connection with the extinguishment of each convertible note. Fair market value of the derivative financial instruments is measured using the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.21% to 2.33%, expected life of 0.27-1.00 years, volatility of 172.67% to 303.06%, and expected dividend yield of zero. The entire amount of derivative instrument liabilities is classified as current due to the fact that settlement of the derivative instruments could be required within twelve months of the balance sheet date. The Company had no derivative financial instruments in the six months ended June 30, 2017.

Shareholders' Deficit

Shareholders' Deficit	6 Months Ended
	Jun. 30, 2018
Shareholders' Deficit [Abstract]
SHAREHOLDERS' DEFICIT	NOTE 11 – SHAREHOLDERS’ DEFICIT Issuance of Common Stock On January 3, 2018, holders of a majority of the voting power of the outstanding capital stock of the Company, acting by written consented, authorized and approved an amendment to the Amended and Restated Articles of Incorporation of the Company increasing the amount of authorized shares of common stock to 500,000,000 shares from 230,000,000 shares. On February 5, 2018, the Company filed the amendment with the Secretary of State of Nevada to effect the increase. On January 11, 2018, the Company sold 588,235 shares of common stock in a private placement transaction to an investor and received $50,000 in proceeds from the sale. The shares were issued at a share price of $0.085 per share. In connection with the stock sales, the Company also issued 588,235 five-year warrants to purchase shares of common stock at an exercise price of $0.15 per share. On February 28, 2018, the Company sold 2,352,942 shares of common stock in private placement transactions to two investors and received $200,000 in proceeds from the sale. The shares were issued at a share price of $0.085 per share. In connection with the stock sales, the Company also issued 1,764,706 five-year warrants to purchase shares of common stock at an exercise price of $0.15 per share. On May 10, 2018, the Company sold 100,000 shares of common stock in private placement transactions to an investor and received $15,500 in proceeds from the sale. The shares were issued at a share price of $0.155 per share. In connection with the stock sale, the Company also issued 50,000 five-year warrants to purchase shares of common stock at an exercise price of $0.25 per share. On June 14, 2018, the Company sold 208,000 shares of common stock in private placement transactions to an investor and received $52,000 in proceeds from the sale. The shares were issued at a share price of $0.25 per share. In connection with the stock sale, the Company also issued 104,000 five-year warrants to purchase shares of common stock at an exercise price of $0.35 per share. During the six months ended June 30, 2018, the Company issued 1,856,480 common shares pursuant to draws made by the Company under the Investment Agreement. The Company received an aggregate of $328,003 in net proceeds from the draws. Common Stock Issuable As of June 30, 2018 and December 31, 2017, the Company was obligated to issue 18,021 and 47,101 shares of common stock, respectively, in exchange for professional services provided by a third party consultant. During the six months ended June 30, 2018 and 2017, the Company recognized expense related to shares earned by the consultant of $27,354 and $28,964, respectively. As of June 30, 2018 and December 31, 2017, the Company was obligated to issue -0- and 75,000 shares, respectively, to an employee pursuant to the EIP. Stock Warrants Transactions involving our stock warrants during the six months ended June 30, 2018 and 2017 are summarized as follows: 2018 2017 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 20,526,387 $ 0.23 10,576,389 $ 0.08 Granted during the period 9,960,403 $ 0.10 7,990,000 $ 0.42 Exercised during the period --- $ --- --- $ --- Terminated during the period --- $ --- --- $ --- Outstanding at end of the period 30,486,790 $ 0.19 18,566,389 $ 0.23 Exercisable at end of the period 30,486,790 $ 0.19 18,566,389 $ 0.23 Weighted average remaining life 4.0 years 4.7 years The following table summarizes information about the Company’s stock warrants outstanding as of June 30, 2018: Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.05 to 0.09 15,192,351 4.2 $ 0.07 15,192,351 $ 0.07 $ 0.10 to 0.15 5,640,441 3.7 $ 0.13 5,640,441 $ 0.13 $ 0.25 to 0.50 8,463,998 3.9 $ 0.33 8,463,998 $ 0.33 $ 0.51 to 1.00 1,190,000 3.8 $ 0.97 1,190,000 $ 0.97 $ 0.05 to 1.00 30,486,790 4.0 $ 0.19 30,486,790 $ 0.19 During the six months ended June 30, 2018, the Company issued 9,960,403 warrants. The fair value of the warrants was calculated using the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 2.32% to 2.83%, expected life of 3-5 years, volatility of 261.18% to 301.64%, and expected dividend yield of zero. The aggregate grant date fair value of warrants issued during the six months ended June 30, 2018 was $705,221. In June 2018, the Company issued 600,000 five-year warrants with an exercise price of $0.15 to two individuals for consulting services to be performed between June 6 and December 6, 2018. The fair value of the warrants was $94,844, which is being recognized on a straight-line basis over the six-month service period. During the six months ended June 30, 2018, the Company recognized general and administrative expense of $12,439 related to these warrants. Employee Equity Incentive Plan On January 1, 2016, the Company instituted the Employee Equity Incentive Plan (the “EIP”) for the purpose of having equity awards available to allow for equity participation by its employees. The EIP allows for the issuance of up to 15,503,680 shares of the Company’s common stock to employees, which may be issued in the form of stock options, stock appreciation rights, or restricted shares. The EIP is governed by the Company’s board, or a committee that may be appointed by the board in the future. The following table summarizes the status of shares issued and outstanding under the EIP outstanding as of and for the six months ended June 30, 2018 and 2017: 2018 2017 Outstanding at beginning of the period 1,498,750 1,552,500 Granted during the period --- --- Terminated during the period --- (110,000 ) Outstanding at end of the period 1,498,750 1,442,500 Shares vested at period-end 1,058,750 813,750 Weighted average grant date fair value of shares granted during the period $ --- $ --- Aggregate grant date fair value of shares granted during the period $ --- $ --- Shares available for grant pursuant to EIP at period-end 11,496,934 11,711,184 Total stock based compensation recognized for grants under the EIP was $6,445 and $6,020 during the six months ended June 30, 2018 and 2017, respectively. Total unrecognized stock compensation related to these grants was $38,335 as of June 30, 2018. A summary of the status of non-vested shares issued pursuant to the EIP as of and for the six months ended June 30, 2018 and 2017 is presented below: 2018 2017 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Nonvested at beginning of period 628,750 $ 0.05 940,000 $ 0.04 Granted --- $ --- --- $ --- Vested (188,750 ) $ 0.04 (207,500 ) $ 0.04 Forfeited --- $ --- (110,000 ) $ 0.05 Nonvested at end of period 440,000 $ 0.05 622,500 $ 0.04 Employee Stock Options The following table summarizes the status of options outstanding as of and for the six months ended June 30, 2018 and 2017: 2018 2017 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 2,349,996 $ 0.12 2,349,996 $ 0.12 Granted during the period 158,000 $ 0.11 --- $ --- Exercised during the period --- $ --- --- $ --- Forfeited during the period --- $ --- --- $ --- Outstanding at end of the period 2,507,996 $ 0.12 2,349,996 $ 0.12 Options exercisable at period-end 836,000 100,000 Weighted average remaining life (in years) 7.9 9.1 Weighted average grant date fair value of options granted during the period $ 0.09 $ --- Options available for grant at period-end 11,496,934 11,711,184 The following table summarizes information about the Company’s stock options outstanding as of June 30, 2018: Options Outstanding Options Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ --- to 0.10 1,733,000 7.6 $ 0.08 783,000 0.08 $ 0.11 to 0.20 774,996 8.5 $ 0.20 53,000 0.19 $ 0.08 to 0.20 2,507,996 7.9 $ 0.12 836,000 $ 0.09 Total stock based compensation recognized related to option grants was $3,223 and $2,750 during the three months ended June 30, 2018 and 2017, respectively, and $6,445 and $5,900 during the six months ended June 30, 2018 and 2017. A summary of the status of non-vested options issued pursuant to the EIP as of and for the six months ended June 30, 2018 and 2017 is presented below: 2018 2017 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Nonvested at beginning of period 1,774,996 $ 0.03 2,249,996 $ 0.03 Granted 158,000 $ 0.09 --- $ --- Vested (261,000 ) $ 0.02 --- $ --- Forfeited --- $ --- --- $ --- Nonvested at end of period 1,671,996 $ 0.03 2,249,996 $ 0.03

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES Service contracts The Company carries various service contracts on its office buildings & certain copier equipment for repairs, maintenance and inspections. All contracts are short term and can be cancelled. Litigation From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not aware of any such legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results. Leases The Company has two real estate leases in Naples, Florida. The Company entered into an operating lease for its main office in Naples, Florida beginning on August 1, 2013 and expiring July 31, 2020. The lease is for a 6901 square-foot space. The base rent for the first full year of the lease term is $251,287 per annum with increases during the period. The Company entered into another operating lease in the same building for an additional 361 square feet space for use of the medical equipment for the same period. The base rent for the first full year of the lease term is $13,140 per annum. During 2017, the Company entered into an agreement with MOD pursuant to which the Company will pay rent to MOD in the amount of $2,040 per month for office space in MOD’s facility used by the Company and its employees. The agreement is effective from January 1, 2017 through July 31, 2018. During the six months ended June 30, 2018 and 2017, the Company recognized rent expense related to the marketing agreement in the amount of $12,240 and $12,240, respectively, pursuant to this agreement and had prepaid an additional $18,217 toward future rent as of June 30, 2018. Total lease expense for the three months ended June, 2018 and 2017 was $68,610 and $78,530, respectively. Total lease expense for the six months ended June, 2018 and 2017 was $146,621 and $140,290, respectively. Future minimum lease payments (excluding real estate taxes and maintenance costs) as of June 30, 2018 are as follows: 2018 (July to December) $ 137,006 2019 273,856 2020 162,055 2021 --- 2022 --- Total $ 572,917 Employment/Consulting Agreements The Company has employment agreements with each of its four physicians. The agreements generally call for a fixed salary at the beginning of the contract with a transaction to performance based pay later in the contract. The contracts expire at various times through 2019, with early termination available upon a notice period of 30-90 days during which compensation is paid to the physician but NWC has no further severance obligation. On July 1, 2016, HLYK entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or HLYK. If Dr. Dent’s employment is terminated by HLYK (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination. On July 1, 2016, HLYK entered into an agreement with Mr. George O’Leary, the Company’s Chief Financial Officer and a member of the Board of Directors, extending his prior agreement with the Company. Mr. O’Leary’s employment agreement continues until terminated by Mr. O’Leary or HLYK. If Mr. O’Leary employment is terminated by HLYK (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Mr. O’Leary will be entitled to receive his base salary and the Company shall maintain his employee benefits for a period of twelve (12) months beginning on the date of termination. In the event that Mr. O’Leary terminates the agreement, he shall be entitled to any accrued by unpaid salary and other benefits up to and including the date of termination. On July 1, 2018, HLYK and Mr. O’Leary entered into an Extension Letter Agreement pursuant to which Mr. O’Leary was increased to full time employment (previously half-time) and agreed to extend the term of his employment to June 30, 2022. In addition to a base salary, the extension provides Mr. O’Leary with certain performance-based cash bonuses, stock grants, and stock option grants.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 13 – SEGMENT REPORTING The Company has two reportable segments: NWC and HLYK. NWC is a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice. The practice’s office is located in Naples, Florida. HLYK plans to operate an online personal medical information and record archive system, the “HealthLynked Network”, which will enable patients and doctors to keep track of medical information via the Internet in a cloud based system. Patients will complete a detailed online personal medical history including past surgical history, medications, allergies, and family history. Once this information is entered patients and their treating physicians will be able to update the information as needed to provide a comprehensive medical history. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Segment information for the three months ended June 30, 2018 and 2017 was as follows: Three Months Ended June 30, 2018 Three Months Ended June 30, 2017 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 566,320 $ --- $ 566,320 $ 516,798 $ --- $ 516,798 Medicare incentives --- --- --- --- --- --- Total revenue 566,320 --- 566,320 516,798 --- 516,798 Operating Expenses Salaries and benefits 348,955 269,188 618,143 334,484 160,647 495,131 General and administrative 190,808 361,775 552,583 213,501 284,877 498,378 Depreciation and amortization 5,575 454 6,029 5,602 257 5,859 Total Operating Expenses 545,338 631,417 1,176,755 553,587 445,781 999,368 Loss from operations $ 20,982 $ (631,417 ) $ (610,435 ) $ (36,789 ) $ (445,781 ) $ (482,570 ) Other Segment Information Interest expense $ 6,005 $ 45,001 $ 51,006 $ 5,603 $ 14,607 $ 20,210 Loss on extinguishment of debt $ --- $ (16,864 ) $ (16,864 ) $ --- $ --- $ --- Loss at inception of convertible notes payable $ --- $ 248,443 $ 248,443 $ --- $ --- $ --- Amortization of original issue and debt discounts on convertible notes $ --- $ 244,563 $ 244,563 $ --- $ 58,524 $ 58,524 Change in fair value of derivative financial instruments $ --- $ 52,786 $ 52,786 $ --- $ --- $ --- Segment information for the six months ended June 30, 2018 and 2017 was as follows: Six Months Ended June 30, 2018 Six Months Ended June 30, 2017 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 1,211,959 $--- $ 1,211,959 $ 992,916 $ --- $ 992,916 Medicare incentives --- --- --- --- --- --- Total revenue 1,211,959 --- 1,211,959 992,916 --- 992,916 Operating Expenses Salaries and benefits 752,010 426,989 1,178,999 679,438 283,567 963,005 General and administrative 416,460 710,951 1,127,411 390,834 497,570 888,404 Depreciation and amortization 11,149 909 12,058 11,257 310 11,567 Total Operating Expenses 1,179,619 1,138,849 2,318,468 1,081,529 781,447 1,862,976 Loss from operations $ 32,340 $ (1,138,849 ) $ (1,106,509 ) $ (88,613 ) $ (781,447 ) $ (870,060 ) Other Segment Information Interest expense $ 11,702 $ 79,651 $ 91,353 $ 11,363 $ 26,434 $ 37,797 Loss on extinguishment of debt $ --- $ 308,359 $ 308,359 $ --- $ --- $ --- Loss at inception of convertible notes payable $ --- $ 440,505 $ 440,505 $ --- $ --- $ --- Amortization of original issue and debt discounts on convertible notes $ --- $ 399,398 $ 399,398 $ --- $ 130,568 $ 130,568 Change in fair value of derivative financial instruments $ --- $ 38,165 $ 38,165 $ --- $ --- $ --- As of June 30, 2018 As of December 31, 2017 Identifiable assets $ 238,025 $ 447,305 $ 685,330 $ 248,255 $ 108,267 $ 356,522 During the three and six months ended June 30, 2018, HLYK recognized revenue of $6,888 related to subscription revenue billed to and paid for by NWC physicians for access to the HealthLynked Network, which the Company test-launched starting in the third quarter of 2017. The revenue for HLYK and related expense for NWC were eliminated on consolidation.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2018
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	NOTE 14 – FAIR VALUE OF FINANCIAL INSTRUMENTS The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their respective fair values due to the short-term nature of such instruments. The Company measures certain financial instruments at fair value on a recurring basis, including certain convertible notes payable and related party loans which were extinguished and reissued and are therefore subject to fair value measurement, as well as derivative financial instruments arising from conversion features embedded in convertible promissory notes for which the conversion rate is not fixed. All financial instruments carried at fair value fall within Level 3 of the fair value hierarchy as their value is based on unobservable inputs. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2018 and December 31, 2017: As of June 30, 2018 Total Level 1 Level 2 Level 3 Fair Value Convertible notes payable $ --- $ --- $ 795,233 $ 795,233 Notes payable to related party --- --- 196,952 196,952 Derivative financial instruments --- --- 1,389,689 1,389,689 Total $ --- $ --- $ 2,381,874 $ 2,381,874 As of December 31, 2017 Total Level 1 Level 2 Level 3 Fair Value Convertible notes payable $ --- $ --- $ --- $ --- Notes payable to related party --- --- --- --- Derivative financial instruments --- --- 398,489 398,489 Total $ --- $ --- $ 398,489 $ 398,489 The changes in Level 3 financial instruments that are measured at fair value on a recurring basis during the three and six months ended June 30, 2018 and 2017 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Convertible notes payable $ (20,921 ) $ --- $ (75,418 ) $ --- Notes payable to related party (4,531 ) --- (7,980 ) --- Derivative financial instruments 52,786 --- 38,165 --- Total $ 27,334 $ --- $ (45,233 ) $ ---

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS On July 11, 2018, the Company issued 200,000 three-year warrants with an exercise price of $0.25 and 300,000 three-year warrants with an exercise price of $0.50 to Iconic in exchange for extending the maturity date of the $550k Note, the $50k Note and the $111k Note until July 31, 2019. On July 13, 2018, the Company issued 175,000 three-year warrants with an exercise price of $0.25 and 75,000 three-year warrants with an exercise price of $0.50 to Iconic in exchange for further extending the maturity date of the $550k Note, the $50k Note and the $111k Note until December 31, 2019. On July 18, 2018, the Company completed a $2,000,000 private placement of common stock and warrants with an accredited investor. The Company issued 3,900,000 shares of common stock, pre-funded warrants to purchase 4,100,000 shares of common stock, and warrants to purchase 8,000,000 shares of common stock, plus additional warrants to purchase shares of common stock that may become exercisable following the registration of the securities issued in the private placement. On August 7, 2018, the Company repaid the $113k Note in full for a total payment of $151,536.

Significant Accounting Polici22

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets and useful life of fixed assets.
Patient Service Revenue	Patient Service Revenue Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected charges. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Company does not believe it is required to provide additional goods or services to the patient. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. The Company determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: ● Medicaid: ● Other: Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement purposes, the Company considers all highly-liquid investments with original maturities of three months or less to be cash and cash equivalents.
Accounts receivable	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 45% of total billings. Trade accounts receivable are recorded at this net amount. As of June 30, 2018 and December 31, 2017, the Company’s gross accounts receivable were $286,728 and $269,501, respectively, and net accounts receivable were $141,853 and $113,349, respectively, based upon net reporting of accounts receivable.
Capital Leases	Capital Leases Costs associated with capitalized leases are capitalized and depreciated ratably over the term of the related useful life of the asset and/or the capital lease term. The related depreciation was $4,587 and $4,587 for the three months ended June 30, 2018 and 2017, respectively, and $9,174 and $9,174 for the six months ended June 30, 2018 and 2017, respectively. Accumulated depreciation of capitalized leases was $312,912 and $303,738 at June 30, 2018 and December 31, 2017, respectively.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. There was no impairment as of June 30, 2018 and December 31, 2017.
Convertible Notes	Convertible Notes Convertible notes are regarded as compound instruments, consisting of a liability component and an equity component. The component parts of compound instruments are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortized cost basis until extinguished upon conversion or at the instrument’s maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized as additional paid-in capital and included in equity, net of income tax effects, and is not subsequently remeasured. After initial measurement, they are carried at amortized cost using the effective interest method. Convertible notes for which the maturity date has been extended and that qualify for debt extinguishment treatment are recorded at fair value on the extinguishment date and then revalue at the end of each reporting period, with the change recorded to the statement of operations under “Change in Fair Value of Debt.”
Derivative Financial Instruments	Derivative Financial Instruments The Company reviews the terms of convertible debt, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received, an immediate charge to income is recognized, in order to initially record the derivative instrument liabilities at their fair value. The discount from the face value of convertible debt instruments resulting from allocating some or all of the proceeds to the derivative instruments is amortized over the life of the instrument through periodic charges to income. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Fair Value of Assets and Liabilities	Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – ● Level 2 ● Level 3 The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods.
Income Taxes	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Recurring Fair Value Measurements	Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, short-term borrowings, accounts payable, accrued liabilities, and derivative financial instruments approximated their fair value.
Net Income (Loss) per Share	Net Income (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three and six month periods ended June 30, 2018 and 2017, the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of June 30, 2018 and 2017, potentially dilutive securities were comprised of (i) 30,486,790 and 18,566,389 warrants outstanding, respectively, (ii) 2,507,996 and 2,349,996 stock options outstanding, respectively, (iii) 13,238,582 and 7,692,143 shares issuable upon conversion of convertible notes, respectively, and (iv) 440,000 and 622,500 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan.
Common stock awards	Common stock awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of comprehensive loss in the same manner and charged to the same account as if such settlements had been made in cash.
Warrants	Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 11, Shareholders’ Deficit
Business Segments	Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has one operating segment due to business similarities and similar economic characteristics.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers — Topic 606 In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments — Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In August 2016, the FASB issued ASC Update No. 2016-15, (Topic 230) Classification of Certain Cash Receipts and Cash Payments. This ASC update provides specific guidance on the presentation of certain cash flow items where there is currently diversity in practice, including, but not limited to, debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, and distributions received from equity method investees. The updated guidance is effective for interim and annual periods beginning after December 15, 2017, and should be applied retrospectively unless impracticable. The Company implemented this guidance effective January 1, 2018. The adoption of ASC Update No. 2016-15 did not have a significant impact on the Company’s statement of cash flows. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash restricted cash or restricted cash equivalents in the statement of cash flows. For public business entities, this ASU is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented. The Company will adopt this standard on January 1, 2018 and will not have a material impact on the Company’s financial statements. In January 2017, the FASB issued ASC Update No. 2017-01, (Topic 805) Business Combinations – Clarifying the Definition of a Business. The amendments in this update provide a more robust framework to use in determining when a set of assets and activities constitute a business. This guidance narrows the definition of a business by providing specific requirements that contribute to the creation of outputs that must be present to be considered a business. The guidance further clarifies the appropriate accounting when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets is that of an acquisition (disposition) of assets, not a business. This framework will reduce the number of transactions that an entity must further evaluate to determine whether transactions are business combinations or asset acquisitions. The updated guidance is effective for interim and annual periods beginning after December 15, 2017, and should be applied on a prospective basis. Early adoption is permitted only for transactions that have not been reported in financial statements that have been issued. The Company implemented this guidance effective January 1, 2018. The implementation of this guidance did not have an effect on the Company’s financial position or results of operations. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company’s financial statements. On December 22, 2017 the SEC staff issued Staff Accounting Bulletin 118 (SAB 118), which provides guidance on accounting for the tax effects of the Tax Cuts and Jobs Act (the TCJA). SAB 118 provides a measurement period that should not extend beyond one year from the enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the TCJA for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the TCJA is incomplete but for which they are able to determine a reasonable estimate, it must record a provisional amount in the financial statements. Provisional treatment is proper in light of anticipated additional guidance from various taxing authorities, the SEC, the FASB, and even the Joint Committee on Taxation. If a company cannot determine a provisional amount to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the TCJA. The Company has applied this guidance to its financial statements. In February 2018, the Financial Accounting Standards Board (“FASB”) issued ASC Update No 2018-02 (Topic 220) Income Statement – Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This ASC update allows for a reclassification into retained earnings of the stranded tax effects in accumulated other comprehensive income (“AOCI”) resulting from the enactment of the Tax Cuts and Jobs Act (“TCJA”). The updated guidance is effective for interim and annual periods beginning after December 15, 2018. The Company is evaluating the impact ASU 2018-09 may have on its condensed consolidated financial statements. In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. This standard amends Accounting Standards Codification 740, Income Taxes (ASC 740) to provide guidance on accounting for the tax effects of the Tax Cuts and Jobs Act (the Tax Reform Act) pursuant to Staff Accounting Bulletin No. 118, which allows companies to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard did not materially impact the Company’s financial statements and related disclosures. In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees and supersedes the guidance in Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. Under ASU 2018-07, equity-classified nonemployee share-based payment awards are measured at the grant date fair value on the grant date The probability of satisfying performance conditions must be considered for equity-classified nonemployee share-based payment awards with such conditions. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the new standard on the Company’s Condensed Consolidated Financial Statements. In July 2018, the FASB issued ASU 2018-09 to provide clarification and correction of errors to the Codification. The amendments in this update cover multiple Accounting Standards Updates. Some topics in the update may require transition guidance with effective dates for annual periods beginning after December 15, 2018. The Company is evaluating the impact ASU 2018-09 may have on its condensed consolidated financial statements.

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Property, Plant, and Equipment [Abstract]
Schedule of property, plant and equipment	June 30, December 31, 2018 2017 Capital Lease equipment $ 343,492 $ 343,492 Telephone equipment 12,308 12,308 Furniture, Transport and Office equipment 436,168 435,967 Total Property, plant and equipment 791,968 791,767 Less: accumulated depreciation (740,449 ) (728,391 ) Property, plant and equipment, net $ 51,519 $ 63,376

Notes Payable and Other Amoun24

Notes Payable and Other Amounts Due to Related Party (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Payable and Other Amounts Due to Related Party [Abstract]
Schedule of amounts due to related parties	June 30, December 31, 2018 2017 Due to related party: Deferred compensation, Dr. Michael Dent $ 300,600 $ 300,600 Accrued interest payable to Dr. Michael Dent 95,853 63,245 Total due to related party 396,453 363,845 Notes payable to related party: Notes payable to Dr. Michael Dent, current portion --- 553,550 Notes payable to Dr. Michael Dent, long term portion 665,452 --- Total notes payable to related party $ 665,452 $ 553,550
Schedule of amount borrowed under unsecured promissory notes	Inception Date Maturity Date Borrower Interest Rate Amount January 12, 2017 January 13, 2019 HLYK 10 % $ 39,295 * January 18, 2017 January 19, 2019 HLYK 10 % 22,454 * January 24, 2017 January 15, 2019 HLYK 10 % 56,136 * February 9, 2017 February 10, 2019 HLYK 10 % 33,363 * April 20, 2017 April 21, 2019 HLYK 10 % 10,911 * June 15, 2017 June 16, 2019 HLYK 10 % 34,793 * August 17, 2017 August 18, 2018 HLYK 10 % 20,000 August 24, 2017 August 25, 2018 HLYK 10 % 37,500 September 7, 2017 September 8, 2018 HLYK 10 % 35,000 September 21, 2017 September 22, 2018 HLYK 10 % 26,500 September 29, 2017 September 30, 2018 HLYK 10 % 12,000 December 21, 2017 December 22, 2018 HLYK 10 % 14,000 January 8, 2018 January 9, 2019 HLYK 10 % 75,000 January 11, 2018 January 12, 2019 HLYK 10 % 9,000 January 26, 2018 January 27, 2019 HLYK 10 % 17,450 January 3, 2014 December 31, 2018 NWC 10 % 222,050 $ 665,452 * - Denotes that note payable is carried at fair value

Capital Lease (Tables)

Capital Lease (Tables)	6 Months Ended
	Jun. 30, 2018
Capital Lease [Abstract]
Schedule of capital lease obligations	June 30, December 31, 2018 2017 Note payable, New Everbank Lease $ 32,109 $ 39,754 Less: note payable, New Everbank Lease (Capital leases), current portion (19,877 ) (18,348 ) Notes payable, bank loans and capital leases, long-term portion $ 12,232 $ 21,406
Schedule of future minimum payments to capital leases	2018 (July to December) $ 10,703 2019 18,348 2020 3,058 2021 --- 2022 --- Total $ 32,109

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2018
Short-term Debt [Line Items]
Schedule of notes payable	June 30, December 31, 2018 2017 $550k Note - July 2016 $ 612,409 * $ 550,000 $50k Note - July 2016 59,771 * 50,000 $111k Note - May 2017 123,053 * 111,000 $53k Note - July 2017 --- 53,000 $35k Note - September 2017 --- 35,000 $55k Note - September 2017 --- 55,000 $53k Note II - October 2017 --- 53,000 $171.5k Note - October 2017 171,500 171,500 $57.8k Note - January 2018 57,750 --- $112.8k Note - February 2018 112,750 --- $83k Note - February 2018 83,000 --- $105k Note - March 2018 105,000 --- $63k Note - April 2018 63,000 --- $57.8k Note - April 2018 57,750 --- $90k Note - April 2018 90,000 --- $53k Note II - April 2018 53,000 --- $68.3k Note - May 2018 68,250 --- $37k Note May 2018 37,000 --- $63k Note II - May 2018 63,000 --- $78.8k Note - May 2018 78,750 --- 1,835,983 1,078,500 Less: unamortized discount (689,883 ) (266,642 ) Convertible notes payable, net of original issue discount and debt discount 1,146,100 811,858 Less: convertible notes payable, long term portion (795,233 ) --- Convertible notes payable, current portion $ 350,867 $ 811,858 * - Denotes that convertible note payable is carried at fair value
Convertible Notes Payable ($53,000) - July 2017 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Cash repayment $ 74,922 Less face value of convertible note payable retired (53,000 ) Less carrying value of derivative financial instruments arising from ECF (53,893 ) Less accrued interest (2,644 ) Plus carrying value of discount at extinguishment 18,427 Gain on extinguishment of debt $ (16,188 )
Convertible Notes Payable ($35,000) - September 2017 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Cash repayment $ 49,502 Less face value of convertible note payable retired (35,000 ) Less carrying value of derivative financial instruments arising from ECF (37,269 ) Less accrued interest (1,716 ) Plus carrying value of discount at extinguishment 12,705 Gain on extinguishment of debt $ (11,778 )
Convertible Notes Payable ($55,000) - September 2017 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Cash repayment $ 85,258 Less face value of convertible note payable retired (55,000 ) Less carrying value of derivative financial instruments arising from ECF (69,687 ) Less accrued interest (2,759 ) Plus carrying value of discount at extinguishment 27,425 Gain on extinguishment of debt $ (14,763 )
Convertible Notes Payable ($53,000) - October 2017 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Cash repayment $ 75,000 Less face value of convertible note payable retired (53,000 ) Less carrying value of derivative financial instruments arising from ECF (55,790 ) Less accrued interest (2,571 ) Plus carrying value of discount at extinguishment 19,496 Gain on extinguishment of debt $ (16,865 )
Convertible Notes Payable ($57,750) - January 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 82,652 Original issue discount and fees 7,750 Financing cost (32,652 ) Convertible note --- Notes payable and bank loans, long-term portion $ 57,750
Convertible Notes Payable ($112,750) - February 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 161,527 Original issue discount and fees 12,750 Financing cost (61,527 ) Convertible note --- Notes payable and bank loans, long-term portion $ 112,750
Convertible Notes Payable ($83,000) - February 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 119,512 Original issue discount and fees 8,000 Financing cost (44,512 ) Convertible note --- Notes payable and bank loans, long-term portion $ 83,000
Convertible Notes Payable ($105,000) - March 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 153,371 Original issue discount and fees 5,000 Financing cost (53,371 ) Convertible note --- Notes payable and bank loans, long-term portion $ 105,000
Convertible Notes Payable ($63,000) - April 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 83,806 Original issue discount and fees 3,000 Financing cost (23,806 ) Convertible note --- Notes payable and bank loans, long-term portion $ 63,000
Convertible Notes Payable ($57,750) - April 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 83,397 Original issue discount and fees 7,750 Financing cost (33,397 ) Convertible note --- Notes payable and bank loans, long-term portion $ 57,750
Convertible Notes Payable ($90,000) - April 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 130,136 Original issue discount and fees 4,500 Financing cost (44,636 ) Convertible note --- Notes payable and bank loans, long-term portion $ 90,000
Convertible Notes Payable ($53,000) - April 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 71,679 Original issue discount and fees 3,000 Financing cost (21,679 ) Convertible note --- Notes payable and bank loans, long-term portion $ 53,000
Convertible Notes Payable ($68,250) - May 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 99,422 Original issue discount and fees 3,250 Financing cost (34,422 ) Convertible note --- Notes payable and bank loans, long-term portion $ 68,250
Convertible Notes Payable ($37,000) - May 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 54,086 Original issue discount and fees 2,000 Financing cost (19,086 ) Convertible note --- Notes payable and bank loans, long-term portion $ 37,000
Convertible Notes Payable ($63,000) - May 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 90,390 Original issue discount and fees 3,000 Financing cost (30,390 ) Convertible note --- Notes payable and bank loans, long-term portion $ 63,000
Convertible Notes Payable ($78,750) - May 2018 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 116,027 Original issue discount and fees 3,750 Financing cost (41,027 ) Convertible note --- Notes payable and bank loans, long-term portion $ 78,750

Derivative Financial Instrume27

Derivative Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2018
Derivative Financial Instruments [Abstract]
Schedule of derivative financial instruments	Change in Fair Value Inception of Fair Value Write off Fair Value as of Derivative of Derivative Derivative as of December 31, Financial Financial Financial June 30, 2017 Instruments Instruments Instruments 2018 $53k Note - July 2017 $ 48,876 $ --- $ 5,017 $ (53,893 ) $ --- $35k Note - September 2017 36,161 --- 1,108 (37,269 ) --- $55k Note - September 2017 64,656 --- 5,032 (69,688 ) --- $53k Note #2 - October 2017 58,216 --- (2,426 ) (55,790 ) --- $171.5k Note - October 2017 190,580 --- (7,953 ) --- 182,627 $57.8k Note - January 2018 --- 82,652 (21,229 ) --- 61,423 $112.8k Note - February 2018 --- 161,527 (8,207 ) --- 153,320 $83k Note - February 2018 --- 119,512 (5,433 ) --- 114,079 $105k Note - March 2018 --- 153,371 (6,482 ) --- 146,889 $63k Note - April 2018 --- 83,806 234 --- 84,040 $57.8k Note - April 2018 --- 83,397 (51 ) --- 83,346 $90k Note - April 2018 --- 130,136 (78 ) --- 130,058 $53k Note II - April 2018 --- 71,679 172 --- 71,851 $68.3k Note - May 2018 --- 99,422 189 --- 99,611 $37k Note May 2018 --- 54,086 11 --- 54,097 $63k Note II - May 2018 --- 90,390 1,721 --- 92,111 $78.8k Note - May 2018 --- 116,027 210 --- 116,237 $ 398,489 $ 1,246,005 $ (38,165 ) $ (216,640 ) $ 1,389,689

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2018
Option Indexed to Issuer's Equity [Line Items]
Schedule of stock warrants	2018 2017 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 20,526,387 $ 0.23 10,576,389 $ 0.08 Granted during the period 9,960,403 $ 0.10 7,990,000 $ 0.42 Exercised during the period --- $ --- --- $ --- Terminated during the period --- $ --- --- $ --- Outstanding at end of the period 30,486,790 $ 0.19 18,566,389 $ 0.23 Exercisable at end of the period 30,486,790 $ 0.19 18,566,389 $ 0.23 Weighted average remaining life 4.0 years 4.7 years
Summary of shares issued and outstanding under the EIP outstanding	2018 2017 Outstanding at beginning of the period 1,498,750 1,552,500 Granted during the period --- --- Terminated during the period --- (110,000 ) Outstanding at end of the period 1,498,750 1,442,500 Shares vested at period-end 1,058,750 813,750 Weighted average grant date fair value of shares granted during the period $ --- $ --- Aggregate grant date fair value of shares granted during the period $ --- $ --- Shares available for grant pursuant to EIP at period-end 11,496,934 11,711,184
Schedule of stock options outstanding	2018 2017 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 2,349,996 $ 0.12 2,349,996 $ 0.12 Granted during the period 158,000 $ 0.11 --- $ --- Exercised during the period --- $ --- --- $ --- Forfeited during the period --- $ --- --- $ --- Outstanding at end of the period 2,507,996 $ 0.12 2,349,996 $ 0.12 Options exercisable at period-end 836,000 100,000 Weighted average remaining life (in years) 7.9 9.1 Weighted average grant date fair value of options granted during the period $ 0.09 $ --- Options available for grant at period-end 11,496,934 11,711,184
Warrant [Member]
Option Indexed to Issuer's Equity [Line Items]
Schedule of stock warrants outstanding	Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.05 to 0.09 15,192,351 4.2 $ 0.07 15,192,351 $ 0.07 $ 0.10 to 0.15 5,640,441 3.7 $ 0.13 5,640,441 $ 0.13 $ 0.25 to 0.50 8,463,998 3.9 $ 0.33 8,463,998 $ 0.33 $ 0.51 to 1.00 1,190,000 3.8 $ 0.97 1,190,000 $ 0.97 $ 0.05 to 1.00 30,486,790 4.0 $ 0.19 30,486,790 $ 0.19
Employee Stock Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Schedule of stock warrants outstanding	Options Outstanding Options Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ --- to 0.10 1,733,000 7.6 $ 0.08 783,000 0.08 $ 0.11 to 0.20 774,996 8.5 $ 0.20 53,000 0.19 $ 0.08 to 0.20 2,507,996 7.9 $ 0.12 836,000 $ 0.09
Summary of nonvested shares issued	2018 2017 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Nonvested at beginning of period 628,750 $ 0.05 940,000 $ 0.04 Granted --- $ --- --- $ --- Vested (188,750 ) $ 0.04 (207,500 ) $ 0.04 Forfeited --- $ --- (110,000 ) $ 0.05 Nonvested at end of period 440,000 $ 0.05 622,500 $ 0.04
Employee Equity Incentive Plan [Member]
Option Indexed to Issuer's Equity [Line Items]
Summary of nonvested shares issued	2018 2017 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Nonvested at beginning of period 1,774,996 $ 0.03 2,249,996 $ 0.03 Granted 158,000 $ 0.09 --- $ --- Vested (261,000 ) $ 0.02 --- $ --- Forfeited --- $ --- --- $ --- Nonvested at end of period 1,671,996 $ 0.03 2,249,996 $ 0.03

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies [Abstract]
Schedule of future minimum lease payments	2018 (July to December) $ 137,006 2019 273,856 2020 162,055 2021 --- 2022 --- Total $ 572,917

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Schedule of segment information	Three Months Ended June 30, 2018 Three Months Ended June 30, 2017 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 566,320 $ --- $ 566,320 $ 516,798 $ --- $ 516,798 Medicare incentives --- --- --- --- --- --- Total revenue 566,320 --- 566,320 516,798 --- 516,798 Operating Expenses Salaries and benefits 348,955 269,188 618,143 334,484 160,647 495,131 General and administrative 190,808 361,775 552,583 213,501 284,877 498,378 Depreciation and amortization 5,575 454 6,029 5,602 257 5,859 Total Operating Expenses 545,338 631,417 1,176,755 553,587 445,781 999,368 Loss from operations $ 20,982 $ (631,417 ) $ (610,435 ) $ (36,789 ) $ (445,781 ) $ (482,570 ) Other Segment Information Interest expense $ 6,005 $ 45,001 $ 51,006 $ 5,603 $ 14,607 $ 20,210 Loss on extinguishment of debt $ --- $ (16,864 ) $ (16,864 ) $ --- $ --- $ --- Loss at inception of convertible notes payable $ --- $ 248,443 $ 248,443 $ --- $ --- $ --- Amortization of original issue and debt discounts on convertible notes $ --- $ 244,563 $ 244,563 $ --- $ 58,524 $ 58,524 Change in fair value of derivative financial instruments $ --- $ 52,786 $ 52,786 $ --- $ --- $ --- Six Months Ended June 30, 2018 Six Months Ended June 30, 2017 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 1,211,959 $--- $ 1,211,959 $ 992,916 $ --- $ 992,916 Medicare incentives --- --- --- --- --- --- Total revenue 1,211,959 --- 1,211,959 992,916 --- 992,916 Operating Expenses Salaries and benefits 752,010 426,989 1,178,999 679,438 283,567 963,005 General and administrative 416,460 710,951 1,127,411 390,834 497,570 888,404 Depreciation and amortization 11,149 909 12,058 11,257 310 11,567 Total Operating Expenses 1,179,619 1,138,849 2,318,468 1,081,529 781,447 1,862,976 Loss from operations $ 32,340 $ (1,138,849 ) $ (1,106,509 ) $ (88,613 ) $ (781,447 ) $ (870,060 ) Other Segment Information Interest expense $ 11,702 $ 79,651 $ 91,353 $ 11,363 $ 26,434 $ 37,797 Loss on extinguishment of debt $ --- $ 308,359 $ 308,359 $ --- $ --- $ --- Loss at inception of convertible notes payable $ --- $ 440,505 $ 440,505 $ --- $ --- $ --- Amortization of original issue and debt discounts on convertible notes $ --- $ 399,398 $ 399,398 $ --- $ 130,568 $ 130,568 Change in fair value of derivative financial instruments $ --- $ 38,165 $ 38,165 $ --- $ --- $ --- As of June 30, 2018 As of December 31, 2017 Identifiable assets $ 238,025 $ 447,305 $ 685,330 $ 248,255 $ 108,267 $ 356,522

Fair Value of Financial Instr31

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of fair value measurements	As of June 30, 2018 Total Level 1 Level 2 Level 3 Fair Value Convertible notes payable $ --- $ --- $ 795,233 $ 795,233 Notes payable to related party --- --- 196,952 196,952 Derivative financial instruments --- --- 1,389,689 1,389,689 Total $ --- $ --- $ 2,381,874 $ 2,381,874 As of December 31, 2017 Total Level 1 Level 2 Level 3 Fair Value Convertible notes payable $ --- $ --- $ --- $ --- Notes payable to related party --- --- --- --- Derivative financial instruments --- --- 398,489 398,489 Total $ --- $ --- $ 398,489 $ 398,489
Level 3 financial instruments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of fair value measurements	Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Convertible notes payable $ (20,921 ) $ --- $ (75,418 ) $ --- Notes payable to related party (4,531 ) --- (7,980 ) --- Derivative financial instruments 52,786 --- 38,165 --- Total $ 27,334 $ --- $ (45,233 ) $ ---

Business and Business Present32

Business and Business Presentation (Details) - shares	1 Months Ended
	Sep. 05, 2014	Jun. 30, 2018	Feb. 05, 2018	Jan. 03, 2018	Dec. 31, 2017	Sep. 03, 2014
Business and Business Presentation (Textual)
Common stock, shares authorized		500,000,000	500,000,000	230,000,000	500,000,000	230,000,000
Preferred stock, shares authorized						20,000,000
Stock issued during period shares acquisitions	50,000,000
Shares authorized						250,000,000
Share Exchange Agreement [Member]
Business and Business Presentation (Textual)
Equity method investment ownership percentage	100.00%

Significant Accounting Polici33

Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Significant Accounting Policies (Textual)
Percentage of customers accounts receivable billings			45.00%
Accounts receivable gross	$ 286,728		$ 286,728		$ 269,501
Accounts receivable net	141,853		141,853		113,349
Depreciation of capitalized leases	4,587	$ 4,587	9,174	$ 9,174
Accumulated depreciation of capitalized leases	$ 312,912		$ 312,912		$ 303,738
Convertible notes [Member]
Significant Accounting Policies (Textual)
Anti-dilutive securities			13,238,582	7,692,143
Stock options [Member]
Significant Accounting Policies (Textual)
Anti-dilutive securities			2,507,996	2,349,996
Warrants [Member]
Significant Accounting Policies (Textual)
Anti-dilutive securities			30,486,790	18,566,389
Unissued shares [Member]
Significant Accounting Policies (Textual)
Anti-dilutive securities			440,000	622,500
Minimum [Member]
Significant Accounting Policies (Textual)
Estimated useful lives			5 years
Maximum [Member]
Significant Accounting Policies (Textual)
Estimated useful lives			7 years
Accounts receivable [Member]
Significant Accounting Policies (Textual)
Concentration risk, percentage			10.00%

Going Concern Matters and Liq34

Going Concern Matters and Liquidity (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 18, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Jul. 31, 2016
Going Concern Matters and Liquidity (Textual)
Working capital deficit				$ 1,883,656
Accumulated deficit		$ (7,096,587)		(7,096,587)		$ (4,705,230)
Net loss		(1,110,249)	$ (561,304)	(2,391,357)	$ (1,038,425)
Net cash used by operating activities				(1,222,947)	(809,636)
Net cash used in investing activities				(201)	(7,046)
Net cash provided by financing activities				1,211,369	777,104
Proceeds from sale of common stock				$ 645,503	$ 520,000
Sale of common stock shares				631,204	101,450
Net proceeds from issuance of convertible notes				$ 805,500	$ 100,000
Proceeds from related party loans				101,450	$ 177,470
HLYK [Member]
Going Concern Matters and Liquidity (Textual)
Proceeds from sale of common stock				$ 327,818
Sale of common stock shares				1,856,480
Investor agreed to purchase of common stock							$ 3,000,000
Proceeds to retire convertible notes payable face value		$ 1,751,750		$ 1,751,750
Subsequent Events [Member]
Going Concern Matters and Liquidity (Textual)
Proceeds from issuance private placement of common stock and warrants	$ 2,000,000
Issuance of common stock	3,900,000
Prefund warrants to purchase shares of common stock	4,100,000
Warrants to purchase shares of common stock	8,000,000

Deferred Offering Costs and P35

Deferred Offering Costs and Prepaid Expenses (Details)	Jun. 06, 2018USD ($)$ / sharesshares	Jun. 07, 2017USD ($)$ / sharesshares	Mar. 22, 2017USD ($)shares	Jul. 07, 2016USD ($)Days$ / shares	Jun. 30, 2018USD ($)$ / shares	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)$ / shares	Jun. 30, 2017USD ($)	Dec. 31, 2017$ / shares
Deferred Offering Costs (Textual)
Common stock par value, per share | $ / shares					$ 0.0001		$ 0.0001		$ 0.0001
Fair of warrants issued for professional service							$ 94,844
General and administrative expense					$ 552,583	$ 498,378	1,127,411	888,404
Warrant [Member]
Deferred Offering Costs (Textual)
Fair of warrants issued for professional service							705,221
Advisor [Member]
Deferred Offering Costs (Textual)
Warrants to purchase of common stock | shares		200,000
Warrants to purchase, per share | $ / shares		$ 0.25
Advisor One [Member]
Deferred Offering Costs (Textual)
Warrants to purchase of common stock | shares		100,000
Warrants to purchase, per share | $ / shares		$ 0.50
Advisor Two [Member]
Deferred Offering Costs (Textual)
Warrants to purchase of common stock | shares		50,000
Warrants to purchase, per share | $ / shares		$ 1
Two Advisor [Member] | Warrant [Member]
Deferred Offering Costs (Textual)
Fair of warrants issued for professional service	$ 94,844
Risk-free interest rate	2.65%
Expected life (in years)	3 years
Expected volatility rate	286.98%
Expected dividend yield	0.00%
Warrants to purchase of common stock | shares	600,000
Warrants to purchase, per share | $ / shares	$ 0.15
General and administrative expense					12,439		12,439
Investment Agreement [Member]
Deferred Offering Costs (Textual)
General and administrative expense					$ 12,802	$ 6,401	$ 25,604	$ 6,401
Investment Agreement [Member] | Accredited Investor [Member]
Deferred Offering Costs (Textual)
Amount invested to purchase of common stock				$ 3,000,000
Common stock par value, per share | $ / shares				$ 0.0001
Purchase price of shares, percentage				80.00%
Common stock, trading days | Days				5
Payments to purchase of common stock				$ 50,000
Warrants exercise prices, description				The warrants were to expire five (5) years from their respective grant dates and have an exercise price equal to 130% of the weighted average purchase price for the respective "$50,000 increment."
Warrants expiration, term				5 years
Warrants exercise price, percentage				130.00%
Amended Investment Agreement [Member] | Investor [Member]
Deferred Offering Costs (Textual)
Warrants exercise prices, description			(i) 4,000,000 shares at $0.25 per share; (ii) 2,000,000 shares at $0.50 per share; and (iii) 1,000,000 shares at $1.00 per share.
Fair of warrants issued for professional service		$ 96,990	$ 56,635
Risk-free interest rate		1.74%	1.95%
Expected life (in years)		5 years	5 years
Expected volatility rate		40.00%	40.00%
Expected dividend yield		0.00%	0.00%
Granting the investor warrants to tender			$ 50,000
Warrants to purchase of common stock | shares			7,000,000

Property, Plant, and Equipmen36

Property, Plant, and Equipment (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	$ 791,968	$ 791,767
Less: accumulated depreciation	(740,449)	(728,391)
Property, plant and equipment, net	51,519	63,376
Capital Lease equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	343,492	343,492
Furniture, Transport and Office equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	436,168	435,967
Telephone equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	$ 12,308	$ 12,308

Property, Plant, and Equipmen37

Property, Plant, and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Property, Plant, and Equipment (Textual)
Depreciation expense	$ 6,029	$ 5,859	$ 12,058	$ 11,567

Notes Payable and Other Amoun38

Notes Payable and Other Amounts Due to Related Party (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Due to related party:
Total due to related party	$ 396,453	$ 363,845
Notes payable to related party:
Notes payable to Dr. Michael Dent, current portion		553,550
Notes payable to Dr. Michael Dent, long term portion	665,452
Total notes payable to related party	665,452	553,550
Deferred compensation, Dr. Michael Dent [Member]
Due to related party:
Total due to related party	300,600	300,600
Accrued interest payable to Dr. Michael Dent [Member]
Due to related party:
Total due to related party	$ 95,853	$ 63,245

Notes Payable and Other Amoun39

Notes Payable and Other Amounts Due to Related Party (Details 1)	6 Months Ended
	Jun. 30, 2018USD ($)
Related Party Transaction [Line Items]
Issuance of unsecured promissory notes, Amount	$ 665,452
Dr. Michael Dent [Member] | Unsecured promissory note [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 12, 2017
Maturity Date	Jan. 13, 2019
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 39,295	[1]
Dr. Michael Dent [Member] | Unsecured promissory note one [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 18, 2017
Maturity Date	Jan. 19, 2019
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 22,454	[1]
Dr. Michael Dent [Member] | Unsecured promissory note two [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 24, 2017
Maturity Date	Jan. 15, 2019
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 56,136	[1]
Dr. Michael Dent [Member] | Unsecured promissory note three [Member]
Related Party Transaction [Line Items]
Inception Date	Feb. 9, 2017
Maturity Date	Feb. 10, 2019
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 33,363	[1]
Dr. Michael Dent [Member] | Unsecured promissory note four [Member]
Related Party Transaction [Line Items]
Inception Date	Apr. 20, 2017
Maturity Date	Apr. 21, 2019
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 10,911	[1]
Dr. Michael Dent [Member] | Unsecured promissory note five [Member]
Related Party Transaction [Line Items]
Inception Date	Jun. 15, 2017
Maturity Date	Jun. 16, 2019
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 34,793	[1]
Dr. Michael Dent [Member] | Unsecured promissory note six [Member]
Related Party Transaction [Line Items]
Inception Date	Aug. 17, 2017
Maturity Date	Aug. 18, 2018
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 20,000
Dr. Michael Dent [Member] | Unsecured promissory note seven [Member]
Related Party Transaction [Line Items]
Inception Date	Aug. 24, 2017
Maturity Date	Aug. 25, 2018
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 37,500
Dr. Michael Dent [Member] | Unsecured promissory note eight [Member]
Related Party Transaction [Line Items]
Inception Date	Sep. 7, 2017
Maturity Date	Sep. 8, 2018
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 35,000
Dr. Michael Dent [Member] | Unsecured promissory note nine [Member]
Related Party Transaction [Line Items]
Inception Date	Sep. 21, 2017
Maturity Date	Sep. 22, 2018
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 26,500
Dr. Michael Dent [Member] | Unsecured promissory note ten [Member]
Related Party Transaction [Line Items]
Inception Date	Sep. 29, 2017
Maturity Date	Sep. 30, 2018
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 12,000
Dr. Michael Dent [Member] | Unsecured promissory note eleven [Member]
Related Party Transaction [Line Items]
Inception Date	Dec. 21, 2017
Maturity Date	Dec. 22, 2018
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 14,000
Dr. Michael Dent [Member] | Unsecured promissory note twelve [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 8, 2018
Maturity Date	Jan. 9, 2019
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 75,000
Dr. Michael Dent [Member] | Unsecured promissory note Thirteen [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 11, 2018
Maturity Date	Jan. 12, 2019
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 9,000
Dr. Michael Dent [Member] | Unsecured promissory note fourteen [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 26, 2018
Maturity Date	Jan. 27, 2019
Borrower	HLYK
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 17,450
Dr. Michael Dent [Member] | Unsecured promissory note fifteen [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 3, 2014
Maturity Date	Dec. 31, 2018
Borrower	NWC
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 222,050
[1]	Denotes that convertible note payable is carried at fair value

Notes Payable and Other Amoun40

Notes Payable and Other Amounts Due to Related Party (Details Textual) - USD ($)	Jul. 13, 2018	Jul. 11, 2018	Jul. 18, 2018	Feb. 12, 2018	Dec. 31, 2014	Aug. 31, 2014	Dec. 31, 2013	Mar. 28, 2012	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Notes Payable and Other Amounts Due to Related Party (Textual)
Issuance of unsecured promissory notes											$ 665,452
Balance of accrued interest on notes payable														$ 22,108
Amount payable									$ 396,453		396,453		$ 363,845
Maturity date, description								DMD agreed to extend the maturity dates of promissory notes with an aggregate face value of $177,500, which were originally scheduled to mature before June 30, 2018, by one year from the original maturity date. Because the fair value of the warrants was greater than 10
General and administrative									552,583	$ 498,378	1,127,411	$ 888,404
Fair value of warrants											94,844
Reissued debt amount									(25,452)		(83,398)
Loss on extinguishment of debt									16,864		(308,359)
Change in fair value of Debt									4,532		$ 7,981
Subsequent Event [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Maturity date, description	Until December 31, 2019.	Until July 31, 2019.
Proceeds from issuance private placement			$ 2,000,000
$750k DMD Note [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Interest rate											10.00%
Interest accrued											$ 55,665		43,963
Dr. Michael Dent [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Interest accrued											$ 40,218		19,350
Maturity date, description											During January 2017, the note was again amended to extend the maturity date until December 31, 2018.
Warrant to purchase of common stock, shares				6,678,462
Increased on unsecured note payable					$ 750,000		$ 500,000
Description of warrants				(i) extend the maturity dates of up to $439,450 loaned by Dr. Dent to the Company in 2017 and 2018 in the form of unsecured promissory notes, including $75,000 loaned from Dr. Dent to the Company in January 2018 to allow the Company to retire an existing convertible promissory note payable to Power-up Lending Group Ltd. before such convertible promissory note became eligible for conversion, and (ii) provide continued loans to the Company. The warrant is immediately exercisable at an exercise price of $0.065 per share, subject to adjustment, and expires five years after the date of issuance.
Fair value of warrants				$ 337,466
Risk-free interest rate				2.56%
Expected life (in years)				5 years
Expected volatility rate				268.90%
Expected dividend yield				0.00%
Reissued debt amount				$ 11,472
Loss on extinguishment of debt				$ 348,938
Dr. Michael Dent [Member] | NWC [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Issuance of unsecured promissory notes						$ 175,000
Interest rate						0.00%
MedOffice Direct (MOD) [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Interest rate											8.00%
Rent paid for office space													$ 2,040
Additional amount towards future rent									18,217		$ 18,217
Rent expense related to the marketing agreement									6,120	6,120	12,240	12,240
Maturity date, description													The Company and its employees for the period from January 1, 2017 through July 31, 2018.
Semi annual fees													$ 25,000
General and administrative									$ 0	$ 25,000	$ 12,500	$ 25,000

Capital Lease (Details)

Capital Lease (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Capital Lease [Abstract]
Note payable, New Everbank Lease	$ 32,109	$ 39,754
Less: note payable, New Everbank Lease (Capital leases), current portion	(19,877)	(18,348)
Notes payable, bank loans and capital leases, long-term portion	$ 12,232	$ 21,406

Capital Lease (Details 1)

Capital Lease (Details 1)	Jun. 30, 2018USD ($)
Capital Lease [Abstract]
2018 (July to December)	$ 10,703
2,019	18,348
2,020	3,058
2,021
2,022
Total	$ 32,109

Capital Lease (Details Textual)

Capital Lease (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Capital Lease (Textual)
Note payable - capital leases		$ 12,232		$ 12,232		$ 21,406
Payments on capital leases		4,587	$ 4,587	7,645	$ 9,174
Everbank [Member]
Capital Lease (Textual)
Note payable - capital leases expiration date	Mar. 31, 2020
Note payable - capital leases		$ 32,109		$ 32,109
Note payable - capital leases monthly payment	$ 1,529
Note payable - capital leases terms	60 months

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Jun. 01, 2018	Dec. 20, 2017	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Notes Payable (Textual)
Discount against the note payable			$ 23,940	$ 23,940	$ 26,881
Note payable			61,869	61,869	$ 70,186
Power Up Lending Group, Ltd. [Member] | Merchant Cash Advance Factoring Agreement [Member]
Notes Payable (Textual)
Advance received for factoring agreement	$ 75,000	$ 75,000
Description of payables in factoring agreement	The Company is required to repay the advance at the rate of $4,048 per week until the balance of $102,000 has been repaid in November 2018.	The Company is required to repay the advance, which acts like an ordinary note payable, at the rate of $4,048 per week until the balance of $102,000 has been repaid in June 2018.
Discount against the note payable	$ 28,500	$ 28,500
Amortization of the discount			$ 4,560	26,881
Recognized to amortize the remaining discount				2,267
Note payable	$ 102,000	$ 102,000
Repayments				$ 89,048

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Jun. 30, 2018		Dec. 31, 2017
Debt Instrument [Line Items]
Total	$ 1,835,983		$ 1,078,500
Less: unamortized discount	(689,883)		(266,642)
Convertible notes payable, net of original issue discount and debt discount	350,867		811,858
Less: convertible notes payable, long term portion	(795,233)
Convertible notes payable, current portion	350,867		811,858
$550k Note - July 2016 [Member]
Debt Instrument [Line Items]
Total	612,409	[1]	550,000
$50k Note - July 2016 [Member]
Debt Instrument [Line Items]
Total	59,771	[1]	50,000
$111k Note - May 2017 [Member]
Debt Instrument [Line Items]
Total	123,053	[1]	111,000
$53k Note - July 2017 [Member]
Debt Instrument [Line Items]
Total			53,000
$35k Note - September 2017 [Member]
Debt Instrument [Line Items]
Total			35,000
$55k Note - September 2017 [Member]
Debt Instrument [Line Items]
Total			55,000
$53k Note #2 - October 2017 [Member]
Debt Instrument [Line Items]
Total			53,000
$171.5k Note - October 2017 [Member]
Debt Instrument [Line Items]
Total	171,500		171,500
$57.8k Note - January 2018 [Member]
Debt Instrument [Line Items]
Total	57,750
$112.8k Note - February 2018 [Member]
Debt Instrument [Line Items]
Total	112,750
$83k Note - February 2018 [Member]
Debt Instrument [Line Items]
Total	83,000
$105k Note - March 2018 [Member]
Debt Instrument [Line Items]
Total	105,000
$63k Note - April 2018 [Member]
Debt Instrument [Line Items]
Total	63,000
$57.8k Note - April 2018 [Member]
Debt Instrument [Line Items]
Total	57,750
$90k Note - April 2018 [Member]
Debt Instrument [Line Items]
Total	90,000
$53k Note II - April 2018 [Member]
Debt Instrument [Line Items]
Total	53,000
$68.3k Note - May 2018 [Member]
Debt Instrument [Line Items]
Total	68,250
$37k Note May 2018 [Member]
Debt Instrument [Line Items]
Total	37,000
$63k Note II - May 2018 [Member]
Debt Instrument [Line Items]
Total	63,000
$78.8k Note - May 2018 [Member]
Debt Instrument [Line Items]
Total	$ 78,750
[1]	Denotes that convertible note payable is carried at fair value

Convertible Notes Payable (De46

Convertible Notes Payable (Details 1) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017
Short-term Debt [Line Items]
Cash repayment		$ 284,682
Gain on extinguishment of debt	$ 16,864	(308,359)
Convertible Notes Payable ($53,000) - July 2017 [Member]
Short-term Debt [Line Items]
Cash repayment		74,922
Less face value of convertible note payable retired		(53,000)
Less carrying value of derivative financial instruments arising from ECF		(53,893)
Less accrued interest		(2,644)
Plus carrying value of discount at extinguishment		18,427
Gain on extinguishment of debt		(16,188)
Convertible Notes Payable ($35,000) - September 2017 [Member]
Short-term Debt [Line Items]
Cash repayment		49,502
Less face value of convertible note payable retired		(35,000)
Less carrying value of derivative financial instruments arising from ECF		(37,269)
Less accrued interest		(1,716)
Plus carrying value of discount at extinguishment		12,705
Gain on extinguishment of debt		(11,778)
Convertible Notes Payable ($55,000) - September 2017 [Member]
Short-term Debt [Line Items]
Cash repayment		85,258
Less face value of convertible note payable retired		(55,000)
Less carrying value of derivative financial instruments arising from ECF		(69,687)
Less accrued interest		(2,759)
Plus carrying value of discount at extinguishment		27,425
Gain on extinguishment of debt		(14,763)
Convertible Notes Payable ($53,000) - October 2017 [Member]
Short-term Debt [Line Items]
Cash repayment		75,000
Less face value of convertible note payable retired		(53,000)
Less carrying value of derivative financial instruments arising from ECF		(55,790)
Less accrued interest		(2,571)
Plus carrying value of discount at extinguishment		19,496
Gain on extinguishment of debt		$ (16,865)

Convertible Notes Payable (De47

Convertible Notes Payable (Details 2) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Short-term Debt [Line Items]
Convertible note	$ 350,867	$ 811,858
Notes payable and bank loans, long-term portion	1,835,983	$ 1,078,500
Convertible Notes Payable ($57,750) - January 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	82,652
Original issue discount and fees	7,750
Financing cost	(32,652)
Notes payable and bank loans, long-term portion	57,750
Convertible Notes Payable ($112,750) - February 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	161,527
Original issue discount and fees	12,750
Financing cost	(61,527)
Notes payable and bank loans, long-term portion	112,750
Convertible Notes Payable ($83,000) - February 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	119,512
Original issue discount and fees	8,000
Financing cost	(44,512)
Notes payable and bank loans, long-term portion	83,000
Convertible Notes Payable ($105,000) - March 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	153,371
Original issue discount and fees	5,000
Financing cost	(53,371)
Notes payable and bank loans, long-term portion	105,000
Convertible Notes Payable ($63,000) - April 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	83,806
Original issue discount and fees	3,000
Financing cost	(23,806)
Notes payable and bank loans, long-term portion	63,000
Convertible Notes Payable ($57,750) - April 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	83,397
Original issue discount and fees	7,750
Financing cost	(33,397)
Notes payable and bank loans, long-term portion	57,750
Convertible Notes Payable ($90,000) - April 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	130,136
Original issue discount and fees	4,500
Financing cost	(44,636)
Notes payable and bank loans, long-term portion	90,000
Convertible Notes Payable ($53,000) - April 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	71,679
Original issue discount and fees	3,000
Financing cost	(21,679)
Notes payable and bank loans, long-term portion	53,000
Convertible Notes Payable ($68,250) - May 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	99,422
Original issue discount and fees	3,250
Financing cost	(34,422)
Notes payable and bank loans, long-term portion	68,250
Convertible Notes Payable ($37,000) - May 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	54,086
Original issue discount and fees	2,000
Financing cost	(19,086)
Notes payable and bank loans, long-term portion	37,000
Convertible Notes Payable ($63,000) - May 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	90,390
Original issue discount and fees	3,000
Financing cost	(30,390)
Notes payable and bank loans, long-term portion	63,000
Convertible Notes Payable ($78,750) - May 2018 [Member]
Short-term Debt [Line Items]
Embedded conversion feature	116,027
Original issue discount and fees	3,750
Financing cost	(41,027)
Notes payable and bank loans, long-term portion	$ 78,750

Convertible Notes Payable (De48

Convertible Notes Payable (Details Textual)	Jul. 10, 2017USD ($)	Jul. 07, 2016USD ($)$ / shares	Mar. 28, 2018USD ($)$ / sharesshares	May 22, 2017USD ($)$ / sharesshares	Mar. 28, 2012	Jun. 30, 2018USD ($)		Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)shares		Jun. 30, 2017USD ($)	Jan. 08, 2018USD ($)	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Convertible secured promissory note face value						$ 1,835,983			$ 1,835,983				$ 1,078,500
Net proceeds from issuance of convertible notes									805,500		$ 100,000
Amortization expense related to discounts						(244,563)		$ (58,524)	(399,398)		(130,568)
Original issue discount						23,940			$ 23,940				26,881
Expected dividend yield									0
Convertible note						350,867			$ 350,867				811,858
Unamortized discount						689,883			689,883				266,642
$550k Note [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value						612,409	[1]		612,409	[1]			550,000
$550k Note [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Percentage of fixed convertible secured promissory note		6.00%
Convertible secured promissory note face value		$ 550,000				612,408			$ 612,408				550,000
Convertible secured promissory note maturity date		Apr. 11, 2017
Common stock fixed price per share | $ / shares		$ 0.08
Net proceeds from issuance of convertible notes		$ 500,000
Original issue discount		$ 50,000
Note convertible into common shares | shares									6,875,000
Interest expense						8,227		8,227	$ 16,364		16,364
Unamortized discount						0			0
$50k Note [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value						59,771	[1]		59,771	[1]			50,000
$50k Note [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Percentage of fixed convertible secured promissory note		10.00%
Convertible secured promissory note face value		$ 50,000				59,771			59,771				50,000
Convertible secured promissory note maturity date		Jul. 11, 2017
Common stock fixed price per share | $ / shares		$ 0.10
Interest expense						1,233		1,233	2,479		2,479
$111k Note [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value						123,053	[1]		123,053	[1]			111,000
Convertible secured promissory note maturity date					Dec. 31, 2019
$111k Note [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Percentage of fixed convertible secured promissory note				10.00%
Convertible secured promissory note face value				$ 111,000
Warrant to purchase of common stock exercise price | $ / shares				$ 0.75
Net proceeds from issuance of convertible notes				$ 100,000
Original issue discount				$ 11,000
Warrant to purchase of common stock, shares | shares				133,333
Note holder fixed price per share | $ / shares				$ 0.35
$111k Note [Member] | HLYK [Member]
Debt Instrument [Line Items]
Convertible secured promissory note maturity date			Jan. 22, 2018
Warrant to purchase of common stock exercise price | $ / shares			$ 0.05
Amortization expense related to discounts						0		12,287	$ 6,931		12,287
Risk-free interest rate			2.59%
Expected life			5 years
Volatility			578.45
Expected dividend yield			0
Note convertible into common shares | shares									317,143
Interest expense						4,078		0	$ 8,246		1,767
Warrant to purchase of common stock, shares | shares			125,000
Fair value of warrants calculated using Black-Scholes pricing model			$ 10,199
Unamortized discount						6,119			6,119
$53k Note III [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value													53,000
$53k Note III [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Percentage of fixed convertible secured promissory note	10.00%
Convertible secured promissory note face value	$ 53,000												$ 53,000
Net proceeds from issuance of convertible notes	50,000
Amortization expense related to discounts						$ 1,520		$ 0	$ 1,520		$ 0
Original issue discount	$ 3,000
Convertible note conversion features, Description	The $53k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the $53k Note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term	The $53k Note has an interest rate of 10% and a default interest rate of 22%.
Accrued interest, for a one-time cash payment												$ 74,922
[1]	Denotes that convertible note payable is carried at fair value

Convertible Notes Payable (De49

Convertible Notes Payable (Details Textual 1)	May 24, 2018USD ($)	May 09, 2018USD ($)	May 07, 2018USD ($)	May 03, 2018USD ($)	Apr. 18, 2018USD ($)	Apr. 16, 2018USD ($)	Apr. 02, 2018USD ($)	Mar. 13, 2018USD ($)	Mar. 05, 2018USD ($)	Feb. 02, 2018USD ($)	Jan. 02, 2018USD ($)	Sep. 11, 2017USD ($)	Sep. 07, 2017USD ($)	Feb. 13, 2018USD ($)	Oct. 27, 2017USD ($)	Oct. 23, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Convertible secured promissory note face value																	$ 1,835,983		$ 1,835,983		$ 1,078,500
Proceeds from issuance of convertible notes																			805,500	$ 100,000
Original issue discount																	23,940		$ 23,940		26,881
Expected dividend yield																			0
Convertible note																	350,867		$ 350,867		811,858
Financing cost																	248,443		440,505
Repayment of notes payable and bank loans																			(113,257)
Unamortized discount																	689,883		689,883		266,642
Loss on extinguishment of debt																	16,864		(308,359)
$35k Note - September 2017 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																					35,000
$35k Note - September 2017 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value													$ 35,000								35,000
Proceeds from issuance of convertible notes													$ 32,000
Convertible note conversion features, Description													The $35k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the $35k Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the $35k Note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term													The $35k Note has an interest rate of 10% and a default interest rate of 20%.
Original issue discount													$ 3,000
Amortization expense related to discount																	614	0	614	0
Interest accrued									$ 49,502
$55k Note - September 2017 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																					55,000
$55k Note - September 2017 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value												$ 55,000									55,000
Convertible note conversion features, Description												The $55k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 60% multiplied by the lowest one (1) trading price for the Common Stock during the twenty (20) trading day period ending on the last complete trading day prior to the date of conversion. If, at any time while the $55k Note is outstanding, the conversion price pursuant to this formula is equal to or lower than $0.10, then an additional ten percent (10%) discount shall be factored into the conversion price until the $55k Note is no longer outstanding. In the event that shares of the Company's Common Stock are not deliverable via DWAC following the conversion of any amount hereunder, an additional ten percent (10%) discount shall be factored into the Variable Conversion Price until the $55k Note is no longer outstanding.
Convertible note interest rate term												The 55k Note has an interest rate of 10% and a default interest rate of 12%.
Original issue discount												$ 7,500
Amortization expense related to discount																	1,085	0	1,085	0
Interest accrued								$ 85,258
$53k Note II - October 2017 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																					53,000
$53k Note II - October 2017 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																$ 53,000					53,000
Proceeds from issuance of convertible notes																50,000
Original issue discount																$ 3,000
Convertible note conversion features, Description																The $53k Note II may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term																The $53k Note II has an interest rate of 10% and a default interest rate of 20% and matures on July 30, 2018.
Amortization expense related to discount																	3,407	0	20,443	0
Interest accrued					$ 75,000
$171.5k Note - October 2017 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	171,500		171,500		171,500
$171.5k Note - October 2017 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value															$ 171,500						171,500
Proceeds from issuance of convertible notes															150,000
Original issue discount															$ 21,500
Convertible note conversion features, Description															The $171.5k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 35% discount to the lowest closing bid price during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the $171.5k Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the $171.5k Note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term															The $171.5k Note has an interest rate of 10% and a default interest rate of 22% and matures on October 26, 2018.
Interest expense																			8,504	0
Amortization expense related to discount																	0	42,875	85,279	0
$58k Note - January 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value											$ 57,750
Proceeds from issuance of convertible notes											50,000
Original issue discount											$ 5,250
Risk-free interest rate											1.83%
Expected life											1 year
Volatility											264.29
Expected dividend yield											0
Financing cost											$ 82,652
Convertible note conversion features, Description											The $58k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company's common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, 200% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term											The $58k Note has an interest rate of 10% and a default interest rate of 18% and matures on January 2, 2019.
Interest expense																	1,440	0	2,832	0
Fair value of warrants calculated using Black-Scholes pricing model											$ 82,652
Net charge on embedded conversion feature											32,652
Unamortized discount											$ 29,429
Amortization expense related to discount																	14,398	0	28,321	0
$113k Note - February 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value										$ 112,750
$113k Note - February 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes										$ 100,000
Risk-free interest rate										1.88%
Expected life										1 year
Volatility										264.93
Expected dividend yield										0
Financing cost										$ 161,527
Convertible note conversion features, Description										The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company's common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, 200% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term										The $113k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 2, 2019.
Interest expense																	2,811	0	4,572	0
Fair value of warrants calculated using Black-Scholes pricing model										$ 161,527
Amortization expense related to discount																	28,110	0	45,718	0
$83k Note - February 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value														$ 83,000			105,000		105,000
Proceeds from issuance of convertible notes														$ 75,000
Risk-free interest rate														1.95%
Expected life														1 year
Volatility														268.44
Expected dividend yield														0
Financing cost														$ 119,512
Convertible note conversion features, Description														The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company's common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 200% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term														The $83k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 13, 2019.
Interest expense																	2,069	0	3,115	0
Fair value of warrants calculated using Black-Scholes pricing model														$ 119,512
Net charge on embedded conversion feature														$ 44,512
Unamortized discount																	71,342		71,342
Amortization expense related to discount																	20,693	0	31,153	0
$105k Note - March 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	105,000		105,000
$105k Note - March 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value									105,000
Proceeds from issuance of convertible notes									$ 100,000
Risk-free interest rate									2.06%
Expected life									1 year
Volatility									278.96
Expected dividend yield									0
Financing cost									$ 153,371
Convertible note conversion features, Description									The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 9.9% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company's common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 110-150% of the outstanding principal and any interest due amount shall be immediately due, depending on the nature of the breach.
Convertible note interest rate term									The $105k Note has an interest rate of 10% and a default interest rate of 24% and matures on March 5, 2019.
Interest expense																	2,618	0	3,366	0
Fair value of warrants calculated using Black-Scholes pricing model									$ 153,371
Net charge on embedded conversion feature									$ 53,371
Amortization expense related to discount																	26,178	0	33,658	0
$63k Note - April 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	63,000		63,000
$63k Note - April 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value							$ 63,000
Proceeds from issuance of convertible notes							$ 60,000
Risk-free interest rate							2.08%
Expected life							9 months 14 days
Volatility							260.76
Expected dividend yield							0
Convertible note conversion features, Description							The $63k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the lowest bid or trading price of the Company's common stock during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach.
Convertible note interest rate term							The $63k Note has an interest rate of 10% and a default interest rate of 22% and matures on January 15, 2019.
Interest expense																	1,536	0	1,536	0
Fair value of warrants calculated using Black-Scholes pricing model							$ 83,806
Loss on extinguishment of debt																			43,531
Amortization expense related to discount																	19,469		19,469
$57.8k Note - April 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	57,750		57,750
$57.8k Note - April 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value						$ 57,750
Risk-free interest rate						2.12%
Expected life						1 year
Volatility						270.41
Expected dividend yield						0
Financing cost						$ 50,000
Convertible note conversion features, Description						The $57.8k Note II Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 40% discount to the lowest bid or trading price of the Company's common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, 200% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach
Convertible note interest rate term						The $57.8k Note II Note has an interest rate of 10% and a default interest rate of 18% and matures on April 16, 2019.
Interest expense																	1,187		1,187
Fair value of warrants calculated using Black-Scholes pricing model						$ 83,897
Unamortized discount																	45,884		45,884
Amortization expense related to discount																	11,866		11,866
$90k Note - April 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	90,000		90,000
$90k Note - April 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value					$ 90,000
Risk-free interest rate					2.17%
Expected life					1 year
Volatility					271.31
Expected dividend yield					0
Financing cost					$ 85,500
Convertible note conversion features, Description					The $90k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 40% discount to the lowest bid or trading price of the Company's common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, the Company would incur a penalty of $250 per day beginning on the fourth day after the conversion notice, increasing to $500 per day beginning on the tenth day. Upon an event of default caused by the Company's breach
Convertible note interest rate term					The $90k Note has an interest rate of 10% and a default interest rate of 24% and matures on April 18, 2019.
Interest expense																	1,800		1,800
Fair value of warrants calculated using Black-Scholes pricing model					$ 130,136
Unamortized discount																	72,000		72,000
Amortization expense related to discount																	18,000		18,000
$53k Note II - April 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	53,000		53,000
$53k Note II - April 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value					$ 53,000
Risk-free interest rate					2.17%
Expected life					9 months 14 days
Volatility					271.31
Expected dividend yield					0
Convertible note conversion features, Description					The $53k Note III may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the lowest bid or trading price of the Company's common stock during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term					The $53k Note III has an interest rate of 10% and a default interest rate of 22% and matures on January 30, 2019.
Interest expense																	1,060		1,060
Fair value of warrants calculated using Black-Scholes pricing model					$ 71,679
Unamortized discount																		39,519		39,519
Amortization expense related to discount																	13,481		13,481
$68.3k Note - May 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	68,250		68,250
$68.3k Note - May 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value				$ 68,250
Risk-free interest rate				2.24%
Expected life				1 year
Volatility				276.40
Expected dividend yield				0
Financing cost				$ 34,422
Convertible note conversion features, Description				The $68.3k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 40% discount to the lowest bid or trading price of the Company's common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, the Company would incur a penalty of $250 per day beginning on the fourth day after the conversion notice, increasing to $500 per day beginning on the tenth day. Upon an event of default caused by the Company's failure to maintain a listing for its common stock, the outstanding principal shall increase by 50%. Upon an event of default caused by the Company's failure to maintain a bid price for its common stock, the outstanding principal shall increase by 20%.
Convertible note interest rate term				The $68.3k Note has an interest rate of 10% and a default interest rate of 24% and matures on May 3, 2019.
Interest expense																	1,085		1,085
Fair value of warrants calculated using Black-Scholes pricing model				$ 99,422
Unamortized discount																	57,434		57,434
Amortization expense related to discount																	10,816		10,816
$37k Note May 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	37,000		37,000
$37k Note May 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value			$ 37,000
Risk-free interest rate			2.25%
Expected life			1 year
Volatility			279.44
Expected dividend yield			0
Financing cost			$ 54,086
Convertible note conversion features, Description			The $37k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 40% discount to the lowest bid or trading price of the Company's common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, the Company would incur a penalty of $250 per day beginning on the fourth day after the conversion notice, increasing to $500 per day beginning on the tenth day. Upon an event of default caused by the Company's failure to maintain a listing for its common stock, the outstanding principal shall increase by 50%. Upon an event of default caused by the Company's failure to maintain a bid price for its common stock, the outstanding principal shall increase by 20
Convertible note interest rate term			The $37k Note has an interest rate of 10% and a default interest rate of 24% and matures on May 7, 2019.
Interest expense																	547		547
Fair value of warrants calculated using Black-Scholes pricing model			$ 54,086
Unamortized discount			$ 31,526
Amortization expense related to discount																	5,474		5,474
$63k Note II - May 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	63,000		63,000
$63k Note II - May 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value		$ 63,000
Risk-free interest rate		2.27%
Expected life		11 months 26 days
Volatility		270.41
Expected dividend yield		0
Financing cost		$ 83,397
Convertible note conversion features, Description		The $63k Note II may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the lowest bid or trading price of the Company's common stock during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach.
Convertible note interest rate term		The $63k Note II has an interest rate of 10% and a default interest rate of 22% and matures on May 7, 2019.
Interest expense																	898		898
Fair value of warrants calculated using Black-Scholes pricing model		$ 90,390
Unamortized discount																		$ 53,975		$ 53,975
Amortization expense related to discount																	9,025		9,025
$78.8k Note - May 2018 [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value																	78,750		78,750
$78.8k Note - May 2018 [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible secured promissory note face value	$ 78,750
Risk-free interest rate	2.28%
Expected life	1 year
Volatility	285.7
Expected dividend yield	0
Financing cost	$ 75,000
Convertible note conversion features, Description	The $78.8k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 40% discount to the lowest bid or trading price of the Company's common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, the Company would incur a penalty of $250 per day beginning on the fourth day after the conversion notice, increasing to $500 per day beginning on the tenth day. Upon an event of default caused by the Company's failure to maintain a listing for its common stock, the outstanding principal shall increase by 50%. Upon an event of default caused by the Company's failure to maintain a bid price for its common stock, the outstanding principal shall increase by 20%. If nto paid at maturity, the amount due under the note increases by 10%.
Convertible note interest rate term	The $78.8k Note has an interest rate of 10% and a default interest rate of 24% and matures on May 24, 2019.
Interest expense																	798		798
Fair value of warrants calculated using Black-Scholes pricing model	$ 116,027
Unamortized discount																	70,767		70,767
Amortization expense related to discount																	$ 7,983		$ 7,983

Derivative Financial Instrume50

Derivative Financial Instruments (Details)	6 Months Ended
	Jun. 30, 2018USD ($)
Debt Instrument [Line Items]
Balance of fair value	$ 398,489
Inception of Derivative Financial Instruments	1,246,005
Change in fair value of Derivative Financial Instruments	(38,165)
Write off Derivative Financial Instruments	(216,640)
Balance of fair value	1,389,689
$53k Note - July 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value	48,876
Inception of Derivative Financial Instruments
Change in fair value of Derivative Financial Instruments	5,017
Write off Derivative Financial Instruments	(53,893)
Balance of fair value
$35k Note - September 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value	36,161
Inception of Derivative Financial Instruments
Change in fair value of Derivative Financial Instruments	1,108
Write off Derivative Financial Instruments	(37,269)
Balance of fair value
$55k Note - September 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value	64,656
Inception of Derivative Financial Instruments
Change in fair value of Derivative Financial Instruments	5,032
Write off Derivative Financial Instruments	(69,688)
Balance of fair value
$53k Note #2 - October 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value	58,216
Inception of Derivative Financial Instruments
Change in fair value of Derivative Financial Instruments	(2,426)
Write off Derivative Financial Instruments	(55,790)
Balance of fair value
$171.5k Note - October 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value	190,580
Inception of Derivative Financial Instruments
Change in fair value of Derivative Financial Instruments	(7,953)
Write off Derivative Financial Instruments
Balance of fair value	182,627
$57.8k Note - January 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	82,652
Change in fair value of Derivative Financial Instruments	(21,229)
Write off Derivative Financial Instruments
Balance of fair value	61,423
$112.8k Note - February 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	161,527
Change in fair value of Derivative Financial Instruments	(8,207)
Write off Derivative Financial Instruments
Balance of fair value	153,320
$83k Note - February 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	119,512
Change in fair value of Derivative Financial Instruments	(5,433)
Write off Derivative Financial Instruments
Balance of fair value	114,079
$105k Note - March 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	153,371
Change in fair value of Derivative Financial Instruments	(6,482)
Write off Derivative Financial Instruments
Balance of fair value	146,889
$63k Note - April 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	83,806
Change in fair value of Derivative Financial Instruments	234
Write off Derivative Financial Instruments
Balance of fair value	84,040
$57.8k Note - April 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	83,397
Change in fair value of Derivative Financial Instruments	(51)
Write off Derivative Financial Instruments
Balance of fair value	83,346
$90k Note - April 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	130,136
Change in fair value of Derivative Financial Instruments	(78)
Write off Derivative Financial Instruments
Balance of fair value	130,058
$53k Note II - April 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	71,679
Change in fair value of Derivative Financial Instruments	172
Write off Derivative Financial Instruments
Balance of fair value	71,851
$68.3k Note - May 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	99,422
Change in fair value of Derivative Financial Instruments	189
Write off Derivative Financial Instruments
Balance of fair value	99,611
$37k Note May 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	54,086
Change in fair value of Derivative Financial Instruments	11
Write off Derivative Financial Instruments
Balance of fair value	54,097
$63k Note II - May 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	90,390
Change in fair value of Derivative Financial Instruments	1,721
Write off Derivative Financial Instruments
Balance of fair value	92,111
$78.8k Note - May 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	116,027
Change in fair value of Derivative Financial Instruments	210
Write off Derivative Financial Instruments
Balance of fair value	$ 116,237

Derivative Financial Instrume51

Derivative Financial Instruments (Details Textual)	6 Months Ended
	Jun. 30, 2018
Derivative Financial Instruments (Textual)
Expected dividend yield	0
Minimum [Member]
Derivative Financial Instruments (Textual)
Risk-free interest rate	1.21%
Expected life	3 months 8 days
Volatility	172.67
Maximum [Member]
Derivative Financial Instruments (Textual)
Risk-free interest rate	2.33%
Expected life	1 year
Volatility	303.06

Shareholders' Deficit (Details)

Shareholders' Deficit (Details) - Stock Warrants [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of the period	20,526,387	10,576,389
Granted during the period	9,960,403	7,990,000
Exercised during the period
Terminated during the period
Outstanding at end of the period	30,486,790	18,566,389
Exercisable at end of the period	30,486,790	18,566,389
Weighted Average Exercise Price, Outstanding at beginning of the period	$ 0.23	$ 0.08
Weighted Average Exercise Price, Granted during the period	0.10	0.42
Weighted Average Exercise Price, Exercised during the period
Weighted Average Exercise Price, Terminated during the period
Weighted Average Exercise Price, Outstanding at end of the period	0.19	0.23
Weighted Average Exercise Price, Exercisable at end of the period	$ 0.19	$ 0.23
Weighted average remaining life	4 years	4 years 8 months 12 days

Shareholders' Deficit (Details

Shareholders' Deficit (Details 1) - Warrant [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	4 years	4 years 8 months 12 days
0.05 to 0.09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	15,192,351
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	4 years 2 months 12 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.07
Warrants/Options Exercisable, Number Exercisable	15,192,351
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.07
0.10 to 0.15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	5,640,441
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	3 years 8 months 12 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.13
Warrants/Options Exercisable, Number Exercisable	5,640,441
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.13
0.25 to 0.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	8,463,998
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	3 years 10 months 25 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.33
Warrants/Options Exercisable, Number Exercisable	8,463,998
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.33
0.51 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	1,190,000
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	3 years 9 months 18 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.97
Warrants/Options Exercisable, Number Exercisable	1,190,000
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.97
0.05 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	29,682,790
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	4 years
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.19
Warrants/Options Exercisable, Number Exercisable	29,682,790
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.19
Maximum [Member] | 0.05 to 0.09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.09
Maximum [Member] | 0.10 to 0.15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.15
Maximum [Member] | 0.25 to 0.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.50
Maximum [Member] | 0.51 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	1
Maximum [Member] | 0.05 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	1
Minimum [Member] | 0.05 to 0.09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.05
Minimum [Member] | 0.10 to 0.15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.10
Minimum [Member] | 0.25 to 0.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.25
Minimum [Member] | 0.51 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.51
Minimum [Member] | 0.05 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.05

Shareholders' Deficit (Detail54

Shareholders' Deficit (Details 2) - EIP [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of the period	1,498,750	1,552,500
Granted during the period
Terminated during the period		(110,000)
Outstanding at end of the period	1,498,750	1,442,500
Shares vested at period-end	1,058,750	813,750
Weighted average grant date fair value of shares granted during the period
Aggregate grant date fair value of shares granted during the period
Shares available for grant pursuant to EIP at period-end	11,496,934	11,711,184

Shareholders' Deficit (Detail55

Shareholders' Deficit (Details 3) - EIP [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested at beginning of period	628,750	940,000
Granted
Vested	(188,750)	(207,500)
Forfeited		(110,000)
Nonvested at end of period	440,000	622,500
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.05	$ 0.04
Weighted Average Grant Date Fair Value, Granted
Weighted Average Grant Date Fair Value, Vested	0.04	0.04
Weighted Average Grant Date Fair Value, Forfeited		0.05
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.05	$ 0.04

Shareholders' Deficit (Detail56

Shareholders' Deficit (Details 4) - Employee Stock Options [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of the period	2,349,996	2,349,996
Granted during the period	158,000
Exercised during the period
Forfeited during the period
Outstanding at end of the period	2,507,996	2,349,996
Weighted Average Exercise Price, Outstanding at beginning of the period	$ 0.12	$ 0.12
Weighted Average Exercise Price, Granted during the period	0.11
Weighted Average Exercise Price, Exercised during the period
Weighted Average Exercise Price, Forfeited during the period
Weighted Average Exercise Price, Outstanding at end of the period	$ 0.12	$ 0.12
Options exercisable at period-end	836,000	100,000
Weighted average remaining life (in years)	7 years 10 months 25 days	9 years 1 month 6 days
Weighted average grant date fair value of options granted during the period	$ 0.09
Options available for grant at period-end	11,496,934	11,711,184

Shareholders' Deficit (Detail57

Shareholders' Deficit (Details 5) - Stock options [Member]	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding | shares	2,349,996
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	7 years 10 months 25 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.12
Warrants/Options Exercisable, Number Exercisable | shares	637,500
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	$ 0.20
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	0.08
- to 0.10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	$ 0.10
Warrants/Options Outstanding, Number Outstanding | shares	1,733,000
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	7 years 7 months 6 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.08
Warrants/Options Exercisable, Number Exercisable | shares	783,000
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.08
0.11 to 0.20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding | shares	774,996
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	8 years 6 months
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.20
Warrants/Options Exercisable, Number Exercisable | shares	53,000
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.19
0.11 to 0.20 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	0.20
0.11 to 0.20 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	0.11
0.08 to 0.20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	$ 2,507,996
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	7 years 10 months 25 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.12
Warrants/Options Exercisable, Number Exercisable | shares	836,000
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.09
0.08 to 0.20 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	0.20
0.08 to 0.20 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	$ 0.08

Shareholders' Deficit (Detail58

Shareholders' Deficit (Details 6) - Employee Stock Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested at beginning of period	1,774,996	2,249,996
Granted	158,000
Vested	(261,000)
Forfeited
Nonvested at end of period	1,671,996	2,249,996
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.03	$ 0.03
Weighted Average Grant Date Fair Value, Granted	0.09
Weighted Average Grant Date Fair Value, Vested	0.02
Weighted Average Grant Date Fair Value, Forfeited
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.03	$ 0.03

Shareholders' Deficit (Detail59

Shareholders' Deficit (Details Textual)	Jun. 14, 2018USD ($)$ / sharesshares	May 10, 2018USD ($)$ / sharesshares	Feb. 28, 2018USD ($)Investor$ / sharesshares	Jan. 11, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2017USD ($)shares	Jun. 30, 2018USD ($)Individuals$ / sharesshares	Jun. 30, 2017USD ($)shares	Dec. 31, 2017shares	Feb. 05, 2018shares	Jan. 03, 2018shares	Sep. 03, 2014shares
Shareholders' Deficit (Textual)
Common stock, shares authorized | shares					500,000,000		500,000,000		500,000,000	500,000,000	230,000,000	230,000,000
Increasing authorized shares of common stock | shares											500,000,000
Aggregate grant date fair value of warrants issued | $							$ 94,844
Fair value of warrant | $							115,125
General and Administrative Expense | $					$ 552,583	$ 498,378	$ 1,127,411	$ 888,404
Warrant [Member]
Shareholders' Deficit (Textual)
Issued warrants | shares							9,960,403	7,990,000
Risk-free interest rate, Minimum							2.32%
Risk-free interest rate, Maximum							2.83%
Expected dividend yield | $							$ 0
Aggregate grant date fair value of warrants issued | $							$ 705,221
Warrant [Member] | Minimum [Member]
Shareholders' Deficit (Textual)
Expected life (in years)							3 years
Expected volatility rate							261.18%
Warrant [Member] | Maximum [Member]
Shareholders' Deficit (Textual)
Expected life (in years)							5 years
Expected volatility rate							301.64%
Five year warrants [Member]
Shareholders' Deficit (Textual)
Issued warrants | shares							600,000
Fair value of warrant | $							$ 94,844
Warrant to purchase of common stock exercise price | $ / shares					$ 0.15		$ 0.15
Warrant terms							5 years
General and Administrative Expense | $							$ 12,439
Number of individuals | Individuals							2
Employee Stock Option [Member]
Shareholders' Deficit (Textual)
Grants shares of common stock | shares					11,496,934	11,711,184	11,496,934	11,711,184
Shares vested at period-end | shares							261,000
Stock based compensation recognized for grants | $					$ 3,223	$ 2,750	$ 6,445	$ 5,900
Employee Equity Incentive Plan [Member]
Shareholders' Deficit (Textual)
Common stock issued for services, shares | shares							15,503,680
Unrecognized stock compensation | $					$ 38,335		$ 38,335
Stock based compensation recognized for grants | $							6,445	6,020
Common Stock [Member]
Shareholders' Deficit (Textual)
Sale of common stock | $							$ 328,003
Sale of stock, shares | shares							1,856,480
Recognized expenses | $							$ 27,354	$ 28,964
Common stock issued for services, shares | shares							18,021		47,101
Warrants to purchase shares of common stock | shares		50,000	1,764,706	588,235
Warrant to purchase of common stock exercise price | $ / shares		$ 0.25	$ 0.15	$ 0.15
Warrant terms		5 years	5 years	5 years
Common Stock [Member] | Private Placement [Member]
Shareholders' Deficit (Textual)
Sale of common stock | $	$ 52,000	$ 15,500	$ 200,000	$ 50,000
Sale of stock, shares | shares	208,000	10,000	2,352,942	588,235
Sale of stock, per share | $ / shares	$ 0.25	$ 0.155	$ 0.085	$ 0.085
Number of investors | Investor			2
Warrants to purchase shares of common stock | shares	104,000
Warrant to purchase of common stock exercise price | $ / shares	$ 0.35
Warrant terms	5 years
Common Stock [Member] | Employee Equity Incentive Plan [Member]
Shareholders' Deficit (Textual)
Obligated to issue shares to employee | shares							0		75,000

Commitments and Contingencies60

Commitments and Contingencies (Details)	Jun. 30, 2018USD ($)
Commitments and Contingencies [Abstract]
2018 (July to December)	$ 137,006
2,019	273,856
2,020	162,055
2,021
2,022
Total	$ 572,917

Commitments and Contingencies61

Commitments and Contingencies (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018USD ($)ft²Segments	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)ft²Segments	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Commitments and Contingencies (Textual)
Operating leases future minimum payments	$ 137,006		$ 137,006
Lease expense, total	$ 68,610	$ 78,530	$ 146,621	$ 140,290
Operating Lease [Member]
Commitments and Contingencies (Textual)
Number of real estate leases | Segments	2		2
Operating Lease [Member] | Naples, Florida [Member]
Commitments and Contingencies (Textual)
Lease beginning date			Aug. 1, 2013
Lease expiration date			Jul. 31, 2020
Area of leasing property | ft²	6,901		6,901
Operating leases future minimum payments	$ 251,287		$ 251,287
Medical Equipment [Member] | Operating Lease [Member]
Commitments and Contingencies (Textual)
Area of leasing property | ft²	361		361
Operating leases future minimum payments	$ 13,140		$ 13,140
MOD [Member]
Commitments and Contingencies (Textual)
Rent paid for office space					$ 2,040
Rent expense related to the marketing agreement	6,120	$ 6,120	12,240	$ 12,240
Additional amount towards future rent	$ 18,217		$ 18,217
Description of lease agreement			The agreement is effective from January 1, 2017 through July 31, 2018.

Segment Reporting (Details)

Segment Reporting (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue
Patient service revenue, net	$ 566,320	$ 516,798	$ 1,211,959	$ 992,916
Medicare incentives
Total revenue	566,320	516,798	1,211,959	992,916
Operating Expenses
Salaries and benefits	618,143	495,131	1,178,999	963,005
General and administrative	552,583	498,378	1,127,411	888,404
Depreciation and amortization	6,029	5,859	12,058	11,567
Total Operating Expenses	1,176,755	999,368	2,318,468	1,862,976
Loss from operations	(610,435)	(482,570)	(1,106,509)	(870,060)
Other Segment Information
Interest expense	51,006	20,210	91,353	37,797
Gain (loss) on extinguishment of debt	16,864		(308,359)
Loss at inception of convertible notes payable	248,443		440,505
Amortization of original issue discount and debt discount on convertible notes	244,563	58,524	399,398	130,568
Change in fair value of derivative financial instruments	52,786		38,165
Identifiable assets	685,330	356,522	685,330	356,522
NWC [Member]
Revenue
Patient service revenue, net	566,320	516,798	1,211,959	992,916
Medicare incentives
Total revenue	566,320	516,798	1,211,959	992,916
Operating Expenses
Salaries and benefits	348,955	334,484	752,010	679,438
General and administrative	190,808	213,501	416,460	390,834
Depreciation and amortization	5,575	5,602	11,149	11,257
Total Operating Expenses	545,338	553,587	1,179,619	1,081,529
Loss from operations	20,982	(36,789)	32,340	(88,613)
Other Segment Information
Interest expense	6,005	5,603	11,702	11,363
Gain (loss) on extinguishment of debt
Loss at inception of convertible notes payable
Amortization of original issue discount and debt discount on convertible notes
Change in fair value of derivative financial instruments
Identifiable assets	238,025	248,255	238,025	248,255
HLYK [Member]
Revenue
Patient service revenue, net
Medicare incentives
Total revenue
Operating Expenses
Salaries and benefits	269,188	160,647	426,989	283,567
General and administrative	361,775	284,877	710,951	497,570
Depreciation and amortization	454	257	909	310
Total Operating Expenses	631,417	445,781	1,138,849	781,447
Loss from operations	(631,417)	(445,781)	(1,138,849)	(781,447)
Other Segment Information
Interest expense	45,001	14,607	79,651	26,434
Gain (loss) on extinguishment of debt	(16,864)		308,359
Loss at inception of convertible notes payable	248,443		440,505
Amortization of original issue discount and debt discount on convertible notes	244,563	58,524	399,398	130,568
Change in fair value of derivative financial instruments	52,786		38,165
Identifiable assets	$ 447,305	$ 108,267	$ 447,305	$ 108,267

Segment Reporting (Details Text

Segment Reporting (Details Textual)	6 Months Ended
	Jun. 30, 2018USD ($)Segments
Segment Reporting (Textual)
Number of reportable segments | Segments	2
HLYK [Member]
Segment Reporting (Textual)
Subscription revenue billed and paid | $	$ 6,888

Fair Value of Financial Instr64

Fair Value of Financial Instruments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Fair Value of Financial Instruments (Textual)
Total	$ 2,381,874		$ 2,381,874		$ 398,489
Level 3 [Member]
Fair Value of Financial Instruments (Textual)
Total	2,381,874		2,381,874		398,489
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings	27,334		(45,233)
Derivative financial instruments [Member]
Fair Value of Financial Instruments (Textual)
Total	1,389,689		1,389,689		398,489
Derivative financial instruments [Member] | Level 1 [Member]
Fair Value of Financial Instruments (Textual)
Total
Derivative financial instruments [Member] | Level 2 [Member]
Fair Value of Financial Instruments (Textual)
Total
Derivative financial instruments [Member] | Level 3 [Member]
Fair Value of Financial Instruments (Textual)
Total	1,389,689		1,389,689		398,489
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings	52,786		38,165
Convertible notes payable [Member]
Fair Value of Financial Instruments (Textual)
Total	795,233		795,233
Convertible notes payable [Member] | Level 1 [Member]
Fair Value of Financial Instruments (Textual)
Total
Convertible notes payable [Member] | Level 2 [Member]
Fair Value of Financial Instruments (Textual)
Total
Convertible notes payable [Member] | Level 3 [Member]
Fair Value of Financial Instruments (Textual)
Total	795,233		795,233
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings	(20,921)		(75,418)
Notes payable to related party [Member]
Fair Value of Financial Instruments (Textual)
Total	196,952		196,952
Notes payable to related party [Member] | Level 1 [Member]
Fair Value of Financial Instruments (Textual)
Total
Notes payable to related party [Member] | Level 2 [Member]
Fair Value of Financial Instruments (Textual)
Total
Notes payable to related party [Member] | Level 3 [Member]
Fair Value of Financial Instruments (Textual)
Total	196,952		196,952
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings	$ (4,531)		$ (7,980)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Aug. 07, 2018	Jul. 13, 2018	Jul. 11, 2018	Jul. 18, 2018	Mar. 28, 2012	Jun. 30, 2018	Jun. 30, 2017
Subsequent Events (Textual)
Maturity date, description					DMD agreed to extend the maturity dates of promissory notes with an aggregate face value of $177,500, which were originally scheduled to mature before June 30, 2018, by one year from the original maturity date. Because the fair value of the warrants was greater than 10
Total payment						$ 284,682
Subsequent Event [Member]
Subsequent Events (Textual)
Proceeds from issuance private placement of common stock and warrants				$ 2,000,000
Issuance of common stock				3,900,000
Prefund warrants to purchase shares of common stock				4,100,000
Warrants to purchase shares of common stock				8,000,000
Maturity date, description		Until December 31, 2019.	Until July 31, 2019.
Subsequent Event [Member] | $550k Note [Member]
Subsequent Events (Textual)
Warrants to purchase shares of common stock		175,000	200,000
Warrant to purchase of common stock exercise price		$ 0.25	$ 0.25
Warrant terms		3 years	3 years
Subsequent Event [Member] | $50k Note [Member]
Subsequent Events (Textual)
Warrants to purchase shares of common stock		175,000	200,000
Warrant to purchase of common stock exercise price		$ 0.25	$ 0.25
Warrant terms		3 years	3 years
Subsequent Event [Member] | $111k Note [Member]
Subsequent Events (Textual)
Warrants to purchase shares of common stock		75,000	300,000
Warrant to purchase of common stock exercise price		$ 0.50	$ 0.50
Warrant terms		3 years	3 years
Total payment	$ 151,536